{"config": {"terminology": {"item": "Researcher", "items": "Researchers", "link": "Publication", "links": "Publications", "link_strength": "Publication collaborations", "total_link_strength": "Total collaborations"}, "templates": {}, "styles": {"description_heading": "color: #757575; font-weight: 600;"}}, "network": {"items": [{"id": "mandatory vaccination policies", "label": "mandatory vaccination policies"}, {"id": "SARS-CoV-2-specific IgG", "label": "SARS-CoV-2-specific IgG"}, {"id": "humoral immune response", "label": "humoral immune response"}, {"id": "herd immunity benefits", "label": "herd immunity benefits"}, {"id": "IgG index values", "label": "IgG index values"}, {"id": "health strategies", "label": "health strategies"}, {"id": "mandatory vaccination", "label": "mandatory vaccination"}, {"id": "non-cooperative solution", "label": "non-cooperative solution"}, {"id": "social hierarchy\u2019s levels", "label": "social hierarchy\u2019s levels"}, {"id": "regular graphs", "label": "regular graphs"}, {"id": "justice", "label": "justice"}, {"id": "distinct symptomatology", "label": "distinct symptomatology"}, {"id": "personality trait scores", "label": "personality trait scores"}, {"id": "health care workers", "label": "health care workers"}, {"id": "closed cohort study", "label": "closed cohort study"}, {"id": "acute respiratory distress syndrome", "label": "acute respiratory distress syndrome"}, {"id": "policy", "label": "policy"}, {"id": "diffusion equation", "label": "diffusion equation"}, {"id": "SARS-CoV-2", "label": "SARS-CoV-2"}, {"id": "virus neutralization test", "label": "virus neutralization test"}, {"id": "mRNA vaccines", "label": "mRNA vaccines"}, {"id": "young adults", "label": "young adults"}, {"id": "COVID-19 patients", "label": "COVID-19 patients"}, {"id": "COVID-19 reinfection", "label": "COVID-19 reinfection"}, {"id": "vaccine development", "label": "vaccine development"}, {"id": "welfare costs", "label": "welfare costs"}, {"id": "new dynamical equations", "label": "new dynamical equations"}, {"id": "post-exposure prophylaxis", "label": "post-exposure prophylaxis"}, {"id": "first dose", "label": "first dose"}, {"id": "immunity duration", "label": "immunity duration"}, {"id": "regular testing", "label": "regular testing"}, {"id": "search space", "label": "search space"}, {"id": "standard mathematical model", "label": "standard mathematical model"}, {"id": "asymptomatic cases", "label": "asymptomatic cases"}, {"id": "vaccine intentions", "label": "vaccine intentions"}, {"id": "past infection", "label": "past infection"}, {"id": "long-term survival", "label": "long-term survival"}, {"id": "underlying psychological processes", "label": "underlying psychological processes"}, {"id": "vaccinated individuals", "label": "vaccinated individuals"}, {"id": "immunisation activities", "label": "immunisation activities"}, {"id": "seropositivity rate", "label": "seropositivity rate"}, {"id": "stochastic simulation", "label": "stochastic simulation"}, {"id": "different messages", "label": "different messages"}, {"id": "severe acute respiratory syndrome coronavirus 2", "label": "severe acute respiratory syndrome coronavirus 2"}, {"id": "seroprevalence rates", "label": "seroprevalence rates"}, {"id": "cross-sectional study", "label": "cross-sectional study"}, {"id": "stochastic multi-agent systems", "label": "stochastic multi-agent systems"}, {"id": "mortality rate", "label": "mortality rate"}, {"id": "severe acute respiratory syndrome", "label": "severe acute respiratory syndrome"}, {"id": "COVID-19 pandemic", "label": "COVID-19 pandemic"}, {"id": "cohort study", "label": "cohort study"}, {"id": "measles outbreak", "label": "measles outbreak"}, {"id": "SARS-CoV-2 infection", "label": "SARS-CoV-2 infection"}, {"id": "poor countries", "label": "poor countries"}, {"id": "SARS-CoV2", "label": "SARS-CoV2"}, {"id": "welfare losses", "label": "welfare losses"}, {"id": "seroprevalence estimates", "label": "seroprevalence estimates"}, {"id": "immune response", "label": "immune response"}, {"id": "dimensional Euclidean lattice", "label": "dimensional Euclidean lattice"}, {"id": "HLA alleles", "label": "HLA alleles"}, {"id": "COVID-19 infection", "label": "COVID-19 infection"}, {"id": "mathematical epidemiology", "label": "mathematical epidemiology"}, {"id": "healthcare professionals", "label": "healthcare professionals"}, {"id": "IgG antibodies", "label": "IgG antibodies"}, {"id": "agnostic view", "label": "agnostic view"}, {"id": "B cells", "label": "B cells"}, {"id": "public health policy", "label": "public health policy"}, {"id": "vaccine-induced immunity", "label": "vaccine-induced immunity"}, {"id": "point estimates", "label": "point estimates"}, {"id": "seroprevalence data", "label": "seroprevalence data"}, {"id": "alternative policies", "label": "alternative policies"}, {"id": "variants of concern", "label": "variants of concern"}, {"id": "healthcare workers", "label": "healthcare workers"}, {"id": "economic activity", "label": "economic activity"}, {"id": "realistic numerical example", "label": "realistic numerical example"}, {"id": "online cross-sectional study", "label": "online cross-sectional study"}, {"id": "side effects", "label": "side effects"}, {"id": "adverse reactions", "label": "adverse reactions"}, {"id": "antibody levels", "label": "antibody levels"}, {"id": "stochastic process", "label": "stochastic process"}, {"id": "statistical physics", "label": "statistical physics"}, {"id": "policy evaluation", "label": "policy evaluation"}, {"id": "benchmark datasets", "label": "benchmark datasets"}, {"id": "topological dimension", "label": "topological dimension"}, {"id": "vaccine strategies", "label": "vaccine strategies"}, {"id": "global herd immunity", "label": "global herd immunity"}, {"id": "number of deaths", "label": "number of deaths"}, {"id": "optimization algorithm", "label": "optimization algorithm"}, {"id": "vaccine acceptability", "label": "vaccine acceptability"}, {"id": "welfare consequences", "label": "welfare consequences"}, {"id": "adaptive immunity", "label": "adaptive immunity"}, {"id": "domestic product", "label": "domestic product"}, {"id": "care workers", "label": "care workers"}, {"id": "mass vaccination", "label": "mass vaccination"}, {"id": "vaccination hesitancy", "label": "vaccination hesitancy"}, {"id": "protective effect", "label": "protective effect"}, {"id": "memory lymphocytes", "label": "memory lymphocytes"}, {"id": "general population", "label": "general population"}, {"id": "epidemic model", "label": "epidemic model"}, {"id": "COVID-19", "label": "COVID-19"}, {"id": "PCR positivity", "label": "PCR positivity"}, {"id": "healthy blood donors", "label": "healthy blood donors"}, {"id": "SARS-CoV-2 immunoglobulin G", "label": "SARS-CoV-2 immunoglobulin G"}, {"id": "acute respiratory syndrome coronavirus 2 infection", "label": "acute respiratory syndrome coronavirus 2 infection"}, {"id": "effective vaccine", "label": "effective vaccine"}, {"id": "immunity threshold", "label": "immunity threshold"}, {"id": "US population", "label": "US population"}, {"id": "public health experts", "label": "public health experts"}, {"id": "greater share", "label": "greater share"}, {"id": "ethics", "label": "ethics"}, {"id": "high antibody titers", "label": "high antibody titers"}, {"id": "population immunity", "label": "population immunity"}, {"id": "countries", "label": "countries"}, {"id": "stochastic SIR model", "label": "stochastic SIR model"}, {"id": "adic number fields", "label": "adic number fields"}, {"id": "clinical trials", "label": "clinical trials"}, {"id": "mathematical analysis", "label": "mathematical analysis"}, {"id": "number of infections", "label": "number of infections"}, {"id": "particle swarm optimization", "label": "particle swarm optimization"}, {"id": "implementation of NPIs", "label": "implementation of NPIs"}, {"id": "vaccination program", "label": "vaccination program"}, {"id": "cellular immunity", "label": "cellular immunity"}, {"id": "health policy", "label": "health policy"}, {"id": "unvaccinated participants", "label": "unvaccinated participants"}, {"id": "poverty accounts", "label": "poverty accounts"}, {"id": "basic reproduction number", "label": "basic reproduction number"}, {"id": "novel SARS-CoV-2 vaccines", "label": "novel SARS-CoV-2 vaccines"}, {"id": "herd immunity", "label": "herd immunity"}, {"id": "vaccine hesitancy", "label": "vaccine hesitancy"}, {"id": "ethical dilemmas", "label": "ethical dilemmas"}, {"id": "SARS-CoV-2 IgG antibody test", "label": "SARS-CoV-2 IgG antibody test"}, {"id": "developed theory", "label": "developed theory"}, {"id": "SARS-CoV-2 antibodies", "label": "SARS-CoV-2 antibodies"}, {"id": "deterministic model", "label": "deterministic model"}, {"id": "blood donors", "label": "blood donors"}, {"id": "electricity market data", "label": "electricity market data"}, {"id": "dynamical evolution", "label": "dynamical evolution"}, {"id": "second dose", "label": "second dose"}, {"id": "social norms", "label": "social norms"}, {"id": "positive externalities", "label": "positive externalities"}, {"id": "COVID-19 vaccine uptake", "label": "COVID-19 vaccine uptake"}, {"id": "individuals' willingness", "label": "individuals' willingness"}, {"id": "COVID-19 vaccine hesitancy", "label": "COVID-19 vaccine hesitancy"}, {"id": "vaccine efficacy", "label": "vaccine efficacy"}, {"id": "presence of anosmia", "label": "presence of anosmia"}, {"id": "COVID-19 vaccine acceptance", "label": "COVID-19 vaccine acceptance"}, {"id": "policy makers", "label": "policy makers"}, {"id": "antiviral drugs", "label": "antiviral drugs"}, {"id": "herd immunity levels", "label": "herd immunity levels"}, {"id": "COVID-19 vaccination acceptance", "label": "COVID-19 vaccination acceptance"}, {"id": "respiratory syndrome coronavirus 2", "label": "respiratory syndrome coronavirus 2"}, {"id": "institutions", "label": "institutions"}, {"id": "SARS-CoV-2-specific antibodies", "label": "SARS-CoV-2-specific antibodies"}, {"id": "free-rider problem", "label": "free-rider problem"}, {"id": "Nash equilibrium", "label": "Nash equilibrium"}, {"id": "SARS-CoV-2 vaccination", "label": "SARS-CoV-2 vaccination"}, {"id": "viral load", "label": "viral load"}, {"id": "immune individuals", "label": "immune individuals"}, {"id": "vaccine candidates", "label": "vaccine candidates"}, {"id": "vaccination rates", "label": "vaccination rates"}, {"id": "global burden", "label": "global burden"}, {"id": "non-pharmaceutical interventions", "label": "non-pharmaceutical interventions"}, {"id": "infection fatality rate", "label": "infection fatality rate"}, {"id": "most countries", "label": "most countries"}, {"id": "respiratory tract", "label": "respiratory tract"}, {"id": "prior infection", "label": "prior infection"}, {"id": "syndrome coronavirus 2", "label": "syndrome coronavirus 2"}, {"id": "prosocial traits", "label": "prosocial traits"}, {"id": "United States", "label": "United States"}, {"id": "BNT162b2 vaccination", "label": "BNT162b2 vaccination"}, {"id": "T cell responses", "label": "T cell responses"}, {"id": "cancer patients", "label": "cancer patients"}, {"id": "antibody response", "label": "antibody response"}, {"id": "massive vaccination", "label": "massive vaccination"}, {"id": "symptom onset", "label": "symptom onset"}, {"id": "network science", "label": "network science"}, {"id": "faster virus clearance", "label": "faster virus clearance"}, {"id": "algebraic structure", "label": "algebraic structure"}, {"id": "more symptoms", "label": "more symptoms"}, {"id": "cell epitopes", "label": "cell epitopes"}, {"id": "serological tests", "label": "serological tests"}, {"id": "high-risk individuals", "label": "high-risk individuals"}, {"id": "COVID-19 vaccination program", "label": "COVID-19 vaccination program"}, {"id": "vaccination strategies", "label": "vaccination strategies"}, {"id": "prosocial nature", "label": "prosocial nature"}, {"id": "infectious (Ct<30) subset", "label": "infectious (Ct<30) subset"}, {"id": "young people", "label": "young people"}, {"id": "SARS-CoV-2 IgG", "label": "SARS-CoV-2 IgG"}, {"id": "vaccine trials", "label": "vaccine trials"}, {"id": "game-theoretic analysis", "label": "game-theoretic analysis"}, {"id": "Sputnik V", "label": "Sputnik V"}, {"id": "COVID-19 vaccination coverage", "label": "COVID-19 vaccination coverage"}, {"id": "antibody titers", "label": "antibody titers"}, {"id": "random walk", "label": "random walk"}, {"id": "long-term care facilities", "label": "long-term care facilities"}, {"id": "angiotensin-converting enzyme 2", "label": "angiotensin-converting enzyme 2"}, {"id": "differential equations", "label": "differential equations"}, {"id": "low prevalence", "label": "low prevalence"}, {"id": "neutralization test", "label": "neutralization test"}, {"id": "existence of hubs", "label": "existence of hubs"}, {"id": "susceptible individuals", "label": "susceptible individuals"}, {"id": "citizens", "label": "citizens"}, {"id": "GDP loss", "label": "GDP loss"}, {"id": "willingness", "label": "willingness"}, {"id": "multi-agent systems", "label": "multi-agent systems"}, {"id": "mathematical model", "label": "mathematical model"}, {"id": "infection fatality ratio", "label": "infection fatality ratio"}, {"id": "SARS-CoV-2 IgG antibodies", "label": "SARS-CoV-2 IgG antibodies"}, {"id": "acute respiratory syndrome coronavirus 2 pandemic", "label": "acute respiratory syndrome coronavirus 2 pandemic"}, {"id": "acute respiratory syndrome coronavirus 2", "label": "acute respiratory syndrome coronavirus 2"}, {"id": "case series", "label": "case series"}, {"id": "asymptomatic SARS-CoV-2 infection", "label": "asymptomatic SARS-CoV-2 infection"}, {"id": "NAb titers", "label": "NAb titers"}, {"id": "systematic review", "label": "systematic review"}, {"id": "deterministic epidemic model", "label": "deterministic epidemic model"}, {"id": "ordinary differential equations", "label": "ordinary differential equations"}, {"id": "infection exposure", "label": "infection exposure"}, {"id": "vaccine rollout", "label": "vaccine rollout"}, {"id": "coronavirus herd immunity optimizer", "label": "coronavirus herd immunity optimizer"}, {"id": "antibody titres", "label": "antibody titres"}, {"id": "SARS-CoV-2 subunit vaccine", "label": "SARS-CoV-2 subunit vaccine"}, {"id": "immune memory", "label": "immune memory"}, {"id": "asymptomatic infection", "label": "asymptomatic infection"}, {"id": "COVID-19 transmission", "label": "COVID-19 transmission"}, {"id": "immunization levels", "label": "immunization levels"}, {"id": "game-theoretic approach", "label": "game-theoretic approach"}, {"id": "Medical Center", "label": "Medical Center"}, {"id": "ODE model", "label": "ODE model"}, {"id": "viral mutations", "label": "viral mutations"}, {"id": "vaccine-elicited antibodies", "label": "vaccine-elicited antibodies"}, {"id": "co-circulating SARS-CoV-2 variant", "label": "co-circulating SARS-CoV-2 variant"}, {"id": "BNT162b2 mRNA COVID-19 vaccine", "label": "BNT162b2 mRNA COVID-19 vaccine"}, {"id": "measles vaccination coverage", "label": "measles vaccination coverage"}, {"id": "non-human primates", "label": "non-human primates"}, {"id": "clinical characteristics", "label": "clinical characteristics"}, {"id": "hospitalization rates", "label": "hospitalization rates"}, {"id": "health professionals", "label": "health professionals"}, {"id": "COVID-19 diagnosis", "label": "COVID-19 diagnosis"}, {"id": "vaccination acceptance", "label": "vaccination acceptance"}, {"id": "age groups", "label": "age groups"}, {"id": "number field", "label": "number field"}, {"id": "SARS-CoV-2 surrogate virus neutralization test", "label": "SARS-CoV-2 surrogate virus neutralization test"}, {"id": "democracy", "label": "democracy"}, {"id": "SARS-CoV-2 pandemic", "label": "SARS-CoV-2 pandemic"}, {"id": "peptide vaccine", "label": "peptide vaccine"}, {"id": "New York City metropolitan area", "label": "New York City metropolitan area"}, {"id": "receptor-binding domain", "label": "receptor-binding domain"}, {"id": "antigen test", "label": "antigen test"}, {"id": "classification accuracy", "label": "classification accuracy"}, {"id": "macroeconomic indicators", "label": "macroeconomic indicators"}, {"id": "risk groups", "label": "risk groups"}, {"id": "public health officials", "label": "public health officials"}, {"id": "asymptomatic forms", "label": "asymptomatic forms"}, {"id": "ethical values", "label": "ethical values"}, {"id": "vaccine characteristics", "label": "vaccine characteristics"}, {"id": "immune system", "label": "immune system"}, {"id": "emergency department", "label": "emergency department"}, {"id": "feature selection", "label": "feature selection"}, {"id": "COVID-19 vaccine effectiveness", "label": "COVID-19 vaccine effectiveness"}, {"id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic", "label": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic"}, {"id": "SARS-CoV-2 variants", "label": "SARS-CoV-2 variants"}, {"id": "infectious diseases", "label": "infectious diseases"}, {"id": "cross-sectional survey", "label": "cross-sectional survey"}, {"id": "neural network", "label": "neural network"}, {"id": "booster dose", "label": "booster dose"}, {"id": "SARS-CoV", "label": "SARS-CoV"}, {"id": "vaccine safety", "label": "vaccine safety"}, {"id": "Monte Carlo approach", "label": "Monte Carlo approach"}, {"id": "memory B cells", "label": "memory B cells"}, {"id": "vaccine refusal", "label": "vaccine refusal"}, {"id": "SIR model", "label": "SIR model"}, {"id": "fatality ratio", "label": "fatality ratio"}, {"id": "moral obligation", "label": "moral obligation"}, {"id": "immunized population", "label": "immunized population"}, {"id": "high risk", "label": "high risk"}, {"id": "World Health Organization", "label": "World Health Organization"}, {"id": "poverty", "label": "poverty"}, {"id": "transplant recipients", "label": "transplant recipients"}, {"id": "surrogate virus neutralization test", "label": "surrogate virus neutralization test"}, {"id": "mathematical modeling", "label": "mathematical modeling"}, {"id": "severe acute respiratory syndrome coronavirus type 2", "label": "severe acute respiratory syndrome coronavirus type 2"}, {"id": "dynamical equations", "label": "dynamical equations"}, {"id": "Delta variant", "label": "Delta variant"}, {"id": "antibody-dependent enhancement", "label": "antibody-dependent enhancement"}, {"id": "numerical solution", "label": "numerical solution"}, {"id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic", "label": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic"}, {"id": "booster vaccination", "label": "booster vaccination"}, {"id": "vaccination intention", "label": "vaccination intention"}, {"id": "vaccination coverage", "label": "vaccination coverage"}, {"id": "COVID-19 vaccine intention", "label": "COVID-19 vaccine intention"}, {"id": "metaheuristic algorithms", "label": "metaheuristic algorithms"}, {"id": "public health strategies", "label": "public health strategies"}, {"id": "COVID-19 vaccine", "label": "COVID-19 vaccine"}, {"id": "herd immunity threshold", "label": "herd immunity threshold"}, {"id": "COVID-19 cases", "label": "COVID-19 cases"}, {"id": "seroprevalence study", "label": "seroprevalence study"}, {"id": "previous SARS-CoV-2 infection", "label": "previous SARS-CoV-2 infection"}, {"id": "coronavirus 2", "label": "coronavirus 2"}, {"id": "SARS-CoV-2-specific IgG antibodies", "label": "SARS-CoV-2-specific IgG antibodies"}, {"id": "enzyme-linked immunosorbent assay", "label": "enzyme-linked immunosorbent assay"}, {"id": "new SARS-CoV-2 variants", "label": "new SARS-CoV-2 variants"}, {"id": "Middle East respiratory syndrome", "label": "Middle East respiratory syndrome"}, {"id": "numerical exercise", "label": "numerical exercise"}, {"id": "mass vaccination campaign", "label": "mass vaccination campaign"}, {"id": "public trust", "label": "public trust"}, {"id": "incidence rate", "label": "incidence rate"}, {"id": "COVID-19 vaccination intention", "label": "COVID-19 vaccination intention"}, {"id": "contact infection", "label": "contact infection"}, {"id": "household contacts", "label": "household contacts"}, {"id": "protective immunity", "label": "protective immunity"}, {"id": "ultrametric spaces", "label": "ultrametric spaces"}, {"id": "personal protective equipment", "label": "personal protective equipment"}, {"id": "SARS-CoV-2 epidemic", "label": "SARS-CoV-2 epidemic"}, {"id": "SARS-CoV-2 vaccines", "label": "SARS-CoV-2 vaccines"}, {"id": "retrospective closed cohort study", "label": "retrospective closed cohort study"}, {"id": "vaccine effectiveness", "label": "vaccine effectiveness"}, {"id": "influenza vaccination coverage", "label": "influenza vaccination coverage"}, {"id": "acute SARS-CoV-2 infection", "label": "acute SARS-CoV-2 infection"}, {"id": "ultrametric model", "label": "ultrametric model"}, {"id": "poverty effects", "label": "poverty effects"}, {"id": "COVID-19 dynamics", "label": "COVID-19 dynamics"}, {"id": "asymptomatic presentation", "label": "asymptomatic presentation"}, {"id": "cumulative incidence", "label": "cumulative incidence"}, {"id": "emergency use authorization", "label": "emergency use authorization"}, {"id": "robustness tests", "label": "robustness tests"}, {"id": "high-throughput serological assays", "label": "high-throughput serological assays"}, {"id": "T cells", "label": "T cells"}, {"id": "Monte Carlo simulations", "label": "Monte Carlo simulations"}, {"id": "Omicron variant", "label": "Omicron variant"}, {"id": "incremental cost-effectiveness ratio", "label": "incremental cost-effectiveness ratio"}, {"id": "power-law dynamics", "label": "power-law dynamics"}, {"id": "years of age", "label": "years of age"}, {"id": "adverse events", "label": "adverse events"}, {"id": "Oxford-AstraZeneca COVID-19 vaccine", "label": "Oxford-AstraZeneca COVID-19 vaccine"}, {"id": "immune cells", "label": "immune cells"}, {"id": "ratio of poverty", "label": "ratio of poverty"}, {"id": "important mathematical models", "label": "important mathematical models"}, {"id": "viral transmission", "label": "viral transmission"}, {"id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection", "label": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection"}, {"id": "positive household contacts", "label": "positive household contacts"}, {"id": "recent SARS-CoV-2 infection", "label": "recent SARS-CoV-2 infection"}, {"id": "SARS-CoV-2 transmission", "label": "SARS-CoV-2 transmission"}, {"id": "mild symptoms", "label": "mild symptoms"}, {"id": "effects of NPIs", "label": "effects of NPIs"}, {"id": "adic diffusion equation", "label": "adic diffusion equation"}, {"id": "cellular immune responses", "label": "cellular immune responses"}, {"id": "COVID-19 vaccination", "label": "COVID-19 vaccination"}, {"id": "SARS-CoV-2 antibody seroprevalence", "label": "SARS-CoV-2 antibody seroprevalence"}, {"id": "percent of GDP", "label": "percent of GDP"}, {"id": "severe disease", "label": "severe disease"}, {"id": "care facilities", "label": "care facilities"}, {"id": "viral infection", "label": "viral infection"}, {"id": "unmet need", "label": "unmet need"}, {"id": "policy analysis", "label": "policy analysis"}, {"id": "growth estimates", "label": "growth estimates"}, {"id": "humoral response", "label": "humoral response"}, {"id": "years age group", "label": "years age group"}, {"id": "critical behavior", "label": "critical behavior"}, {"id": "SARS-CoV-2 virus", "label": "SARS-CoV-2 virus"}, {"id": "new mathematical model", "label": "new mathematical model"}, {"id": "SIR equations", "label": "SIR equations"}, {"id": "search optimization", "label": "search optimization"}, {"id": "SARS-CoV-2 T-cell response", "label": "SARS-CoV-2 T-cell response"}, {"id": "logistic regression analysis", "label": "logistic regression analysis"}, {"id": "health workers", "label": "health workers"}, {"id": "SARS-CoV-2 seroprevalence", "label": "SARS-CoV-2 seroprevalence"}, {"id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies", "label": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies"}, {"id": "vaccine acceptance", "label": "vaccine acceptance"}, {"id": "SARS-CoV-2 immune response", "label": "SARS-CoV-2 immune response"}, {"id": "vaccine policy", "label": "vaccine policy"}, {"id": "vaccination campaign", "label": "vaccination campaign"}, {"id": "fatality rate", "label": "fatality rate"}, {"id": "common good", "label": "common good"}, {"id": "epidemic dynamics", "label": "epidemic dynamics"}, {"id": "mRNA vaccine recipients", "label": "mRNA vaccine recipients"}, {"id": "T cell epitopes", "label": "T cell epitopes"}, {"id": "vaccine uptake", "label": "vaccine uptake"}], "links": [{"source_id": "T cells", "target_id": "memory lymphocytes", "strength": 2}, {"source_id": "herd immunity", "target_id": "vaccinated individuals", "strength": 2}, {"source_id": "Delta variant", "target_id": "SARS-CoV-2", "strength": 6}, {"source_id": "Delta variant", "target_id": "Omicron variant", "strength": 3}, {"source_id": "non-pharmaceutical interventions", "target_id": "vaccination rates", "strength": 2}, {"source_id": "COVID-19 vaccine", "target_id": "World Health Organization", "strength": 3}, {"source_id": "herd immunity", "target_id": "herd immunity threshold", "strength": 16}, {"source_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection", "target_id": "herd immunity", "strength": 4}, {"source_id": "acute respiratory syndrome coronavirus 2 infection", "target_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection", "strength": 21}, {"source_id": "acute respiratory syndrome coronavirus 2 infection", "target_id": "SARS-CoV-2 IgG antibodies", "strength": 3}, {"source_id": "herd immunity", "target_id": "acute respiratory syndrome coronavirus 2 infection", "strength": 4}, {"source_id": "herd immunity", "target_id": "SARS-CoV-2 IgG antibodies", "strength": 4}, {"source_id": "SARS-CoV-2 virus", "target_id": "herd immunity", "strength": 4}, {"source_id": "SARS-CoV-2", "target_id": "infection fatality rate", "strength": 2}, {"source_id": "infection fatality rate", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "vaccine hesitancy", "target_id": "COVID-19 vaccine", "strength": 22}, {"source_id": "cross-sectional survey", "target_id": "vaccine hesitancy", "strength": 3}, {"source_id": "COVID-19 vaccine hesitancy", "target_id": "adverse reactions", "strength": 2}, {"source_id": "COVID-19 vaccine hesitancy", "target_id": "vaccination campaign", "strength": 2}, {"source_id": "COVID-19 vaccine", "target_id": "adverse reactions", "strength": 3}, {"source_id": "vaccine hesitancy", "target_id": "World Health Organization", "strength": 2}, {"source_id": "adverse reactions", "target_id": "COVID-19 vaccine", "strength": 3}, {"source_id": "vaccination campaign", "target_id": "COVID-19 vaccine hesitancy", "strength": 2}, {"source_id": "prosocial nature", "target_id": "underlying psychological processes", "strength": 3}, {"source_id": "prosocial nature", "target_id": "prosocial traits", "strength": 2}, {"source_id": "prosocial nature", "target_id": "COVID-19 vaccination", "strength": 3}, {"source_id": "different messages", "target_id": "young people", "strength": 2}, {"source_id": "COVID-19 vaccination", "target_id": "underlying psychological processes", "strength": 3}, {"source_id": "COVID-19 vaccination", "target_id": "prosocial nature", "strength": 3}, {"source_id": "COVID-19 vaccination intention", "target_id": "vaccination intention", "strength": 6}, {"source_id": "vaccination intention", "target_id": "COVID-19 vaccination intention", "strength": 6}, {"source_id": "herd immunity", "target_id": "COVID-19 vaccine", "strength": 17}, {"source_id": "SARS-CoV-2 vaccination", "target_id": "severe acute respiratory syndrome coronavirus type 2", "strength": 2}, {"source_id": "IgG antibodies", "target_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection", "strength": 3}, {"source_id": "IgG antibodies", "target_id": "SARS-CoV-2 IgG antibodies", "strength": 9}, {"source_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection", "target_id": "IgG antibodies", "strength": 3}, {"source_id": "SARS-CoV-2 virus", "target_id": "population immunity", "strength": 3}, {"source_id": "COVID-19 vaccine", "target_id": "COVID-19 vaccination", "strength": 11}, {"source_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic", "target_id": "herd immunity", "strength": 2}, {"source_id": "vaccination intention", "target_id": "herd immunity", "strength": 2}, {"source_id": "COVID-19", "target_id": "effective vaccine", "strength": 2}, {"source_id": "blood donors", "target_id": "healthcare workers", "strength": 2}, {"source_id": "healthy blood donors", "target_id": "herd immunity", "strength": 2}, {"source_id": "blood donors", "target_id": "seroprevalence rates", "strength": 3}, {"source_id": "herd immunity", "target_id": "healthy blood donors", "strength": 2}, {"source_id": "new dynamical equations", "target_id": "SIR model", "strength": 2}, {"source_id": "deterministic epidemic model", "target_id": "new dynamical equations", "strength": 2}, {"source_id": "deterministic epidemic model", "target_id": "network science", "strength": 2}, {"source_id": "dynamical equations", "target_id": "SIR model", "strength": 2}, {"source_id": "vaccine-induced immunity", "target_id": "vaccine-elicited antibodies", "strength": 2}, {"source_id": "vaccine-induced immunity", "target_id": "mRNA vaccine recipients", "strength": 2}, {"source_id": "population immunity", "target_id": "SARS-CoV-2 variants", "strength": 2}, {"source_id": "population immunity", "target_id": "vaccine-induced immunity", "strength": 2}, {"source_id": "vaccination coverage", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "herd immunity", "target_id": "Delta variant", "strength": 4}, {"source_id": "COVID-19 vaccination", "target_id": "COVID-19 infection", "strength": 3}, {"source_id": "vaccination coverage", "target_id": "COVID-19 vaccination coverage", "strength": 2}, {"source_id": "cross-sectional study", "target_id": "herd immunity", "strength": 2}, {"source_id": "vaccine uptake", "target_id": "cross-sectional study", "strength": 2}, {"source_id": "unmet need", "target_id": "COVID-19 vaccine", "strength": 2}, {"source_id": "unmet need", "target_id": "cross-sectional study", "strength": 2}, {"source_id": "herd immunity", "target_id": "online cross-sectional study", "strength": 2}, {"source_id": "COVID-19 infection", "target_id": "incidence rate", "strength": 2}, {"source_id": "incidence rate", "target_id": "prior infection", "strength": 2}, {"source_id": "COVID-19", "target_id": "COVID-19 cases", "strength": 3}, {"source_id": "health professionals", "target_id": "COVID-19 vaccine", "strength": 2}, {"source_id": "vaccination coverage", "target_id": "measles outbreak", "strength": 2}, {"source_id": "population immunity", "target_id": "vaccination coverage", "strength": 2}, {"source_id": "welfare costs", "target_id": "ratio of poverty", "strength": 2}, {"source_id": "welfare costs", "target_id": "welfare consequences", "strength": 2}, {"source_id": "welfare costs", "target_id": "greater share", "strength": 2}, {"source_id": "welfare costs", "target_id": "growth estimates", "strength": 2}, {"source_id": "most countries", "target_id": "poor countries", "strength": 2}, {"source_id": "most countries", "target_id": "growth estimates", "strength": 2}, {"source_id": "welfare losses", "target_id": "growth estimates", "strength": 2}, {"source_id": "poverty effects", "target_id": "most countries", "strength": 2}, {"source_id": "poverty accounts", "target_id": "most countries", "strength": 2}, {"source_id": "agnostic view", "target_id": "poor countries", "strength": 2}, {"source_id": "agnostic view", "target_id": "countries", "strength": 2}, {"source_id": "COVID-19 pandemic", "target_id": "ratio of poverty", "strength": 2}, {"source_id": "COVID-19 pandemic", "target_id": "agnostic view", "strength": 2}, {"source_id": "growth estimates", "target_id": "ratio of poverty", "strength": 2}, {"source_id": "growth estimates", "target_id": "welfare consequences", "strength": 2}, {"source_id": "growth estimates", "target_id": "agnostic view", "strength": 2}, {"source_id": "herd immunity", "target_id": "COVID-19 transmission", "strength": 2}, {"source_id": "second dose", "target_id": "side effects", "strength": 2}, {"source_id": "COVID-19 vaccine", "target_id": "COVID-19", "strength": 4}, {"source_id": "COVID-19", "target_id": "COVID-19 vaccine", "strength": 4}, {"source_id": "herd immunity threshold", "target_id": "contact infection", "strength": 6}, {"source_id": "immunized population", "target_id": "herd immunity threshold", "strength": 4}, {"source_id": "contact infection", "target_id": "herd immunity threshold", "strength": 6}, {"source_id": "mathematical model", "target_id": "adic diffusion equation", "strength": 4}, {"source_id": "mathematical model", "target_id": "standard mathematical model", "strength": 5}, {"source_id": "mathematical model", "target_id": "ultrametric spaces", "strength": 7}, {"source_id": "diffusion equation", "target_id": "adic number fields", "strength": 4}, {"source_id": "adic diffusion equation", "target_id": "mathematical model", "strength": 4}, {"source_id": "adic diffusion equation", "target_id": "new mathematical model", "strength": 4}, {"source_id": "new mathematical model", "target_id": "diffusion equation", "strength": 4}, {"source_id": "new mathematical model", "target_id": "adic number fields", "strength": 4}, {"source_id": "new mathematical model", "target_id": "number field", "strength": 4}, {"source_id": "standard mathematical model", "target_id": "adic number fields", "strength": 4}, {"source_id": "standard mathematical model", "target_id": "algebraic structure", "strength": 4}, {"source_id": "standard mathematical model", "target_id": "SIR model", "strength": 5}, {"source_id": "adic number fields", "target_id": "social hierarchy\u2019s levels", "strength": 4}, {"source_id": "statistical physics", "target_id": "standard mathematical model", "strength": 4}, {"source_id": "statistical physics", "target_id": "adic number fields", "strength": 4}, {"source_id": "ultrametric spaces", "target_id": "adic diffusion equation", "strength": 4}, {"source_id": "ultrametric spaces", "target_id": "algebraic structure", "strength": 4}, {"source_id": "number field", "target_id": "algebraic structure", "strength": 4}, {"source_id": "SIR model", "target_id": "new mathematical model", "strength": 5}, {"source_id": "SARS-CoV-2", "target_id": "antibody-dependent enhancement", "strength": 4}, {"source_id": "susceptible individuals", "target_id": "contact infection", "strength": 4}, {"source_id": "Monte Carlo simulations", "target_id": "stochastic process", "strength": 2}, {"source_id": "numerical solution", "target_id": "Monte Carlo simulations", "strength": 2}, {"source_id": "COVID-19 pandemic", "target_id": "health policy", "strength": 2}, {"source_id": "common good", "target_id": "moral obligation", "strength": 2}, {"source_id": "policy makers", "target_id": "policy", "strength": 2}, {"source_id": "moral obligation", "target_id": "justice", "strength": 2}, {"source_id": "policy", "target_id": "alternative policies", "strength": 3}, {"source_id": "COVID-19 vaccine", "target_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection", "strength": 4}, {"source_id": "mRNA vaccines", "target_id": "adverse reactions", "strength": 2}, {"source_id": "side effects", "target_id": "mRNA vaccines", "strength": 3}, {"source_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection", "target_id": "mRNA vaccines", "strength": 2}, {"source_id": "existence of hubs", "target_id": "point estimates", "strength": 2}, {"source_id": "dynamical evolution", "target_id": "ODE model", "strength": 2}, {"source_id": "mathematical modeling", "target_id": "multi-agent systems", "strength": 2}, {"source_id": "variants of concern", "target_id": "COVID-19 vaccine", "strength": 4}, {"source_id": "variants of concern", "target_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection", "strength": 2}, {"source_id": "clinical trials", "target_id": "COVID-19 vaccine", "strength": 4}, {"source_id": "clinical trials", "target_id": "herd immunity", "strength": 3}, {"source_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection", "target_id": "variants of concern", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "cross-sectional study", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "health care workers", "strength": 6}, {"source_id": "SARS-CoV-2", "target_id": "SARS-CoV-2 infection", "strength": 11}, {"source_id": "SARS-CoV-2", "target_id": "high risk", "strength": 3}, {"source_id": "high risk", "target_id": "SARS-CoV-2", "strength": 3}, {"source_id": "viral transmission", "target_id": "herd immunity", "strength": 2}, {"source_id": "SARS-CoV-2 infection", "target_id": "second dose", "strength": 3}, {"source_id": "SARS-CoV-2 infection", "target_id": "BNT162b2 mRNA COVID-19 vaccine", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "second dose", "strength": 2}, {"source_id": "immunity duration", "target_id": "vaccination rates", "strength": 3}, {"source_id": "SARS-CoV-2", "target_id": "seroprevalence rates", "strength": 3}, {"source_id": "SARS-CoV-2 transmission", "target_id": "herd immunity", "strength": 2}, {"source_id": "COVID-19 vaccine hesitancy", "target_id": "side effects", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "COVID-19 patients", "strength": 3}, {"source_id": "viral load", "target_id": "SARS-CoV-2", "strength": 3}, {"source_id": "SARS-CoV-2", "target_id": "IgG antibodies", "strength": 6}, {"source_id": "topological dimension", "target_id": "critical behavior", "strength": 2}, {"source_id": "acute respiratory syndrome coronavirus 2", "target_id": "syndrome coronavirus 2", "strength": 3}, {"source_id": "respiratory syndrome coronavirus 2", "target_id": "acute respiratory syndrome coronavirus 2", "strength": 3}, {"source_id": "syndrome coronavirus 2", "target_id": "respiratory syndrome coronavirus 2", "strength": 3}, {"source_id": "coronavirus 2", "target_id": "acute respiratory syndrome coronavirus 2", "strength": 3}, {"source_id": "coronavirus 2", "target_id": "syndrome coronavirus 2", "strength": 3}, {"source_id": "immune response", "target_id": "herd immunity", "strength": 3}, {"source_id": "SARS-CoV-2 antibodies", "target_id": "COVID-19", "strength": 4}, {"source_id": "general population", "target_id": "vaccination program", "strength": 2}, {"source_id": "random walk", "target_id": "social hierarchy\u2019s levels", "strength": 3}, {"source_id": "random walk", "target_id": "COVID-19 dynamics", "strength": 2}, {"source_id": "social hierarchy\u2019s levels", "target_id": "COVID-19 dynamics", "strength": 2}, {"source_id": "developed theory", "target_id": "SIR model", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "protective effect", "strength": 2}, {"source_id": "SARS-CoV2", "target_id": "IgG antibodies", "strength": 2}, {"source_id": "herd immunity", "target_id": "immune cells", "strength": 2}, {"source_id": "non-pharmaceutical interventions", "target_id": "vaccine efficacy", "strength": 2}, {"source_id": "global herd immunity", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "SARS-CoV-2 infection", "target_id": "COVID-19 cases", "strength": 3}, {"source_id": "COVID-19 cases", "target_id": "SARS-CoV-2 infection", "strength": 3}, {"source_id": "previous SARS-CoV-2 infection", "target_id": "SARS-CoV-2 infection", "strength": 2}, {"source_id": "mortality rate", "target_id": "hospitalization rates", "strength": 2}, {"source_id": "hospitalization rates", "target_id": "infection exposure", "strength": 2}, {"source_id": "SARS-CoV-2 IgG", "target_id": "seroprevalence study", "strength": 3}, {"source_id": "systematic review", "target_id": "SARS-CoV-2", "strength": 4}, {"source_id": "SARS-CoV-2 infection", "target_id": "vaccine effectiveness", "strength": 3}, {"source_id": "unvaccinated participants", "target_id": "vaccine effectiveness", "strength": 2}, {"source_id": "general population", "target_id": "SARS-CoV-2 infection", "strength": 5}, {"source_id": "receptor-binding domain", "target_id": "non-human primates", "strength": 2}, {"source_id": "healthcare workers", "target_id": "herd immunity", "strength": 3}, {"source_id": "mass vaccination campaign", "target_id": "vaccine hesitancy", "strength": 2}, {"source_id": "mass vaccination campaign", "target_id": "vaccine refusal", "strength": 2}, {"source_id": "herd immunity benefits", "target_id": "vaccination campaign", "strength": 2}, {"source_id": "vaccine characteristics", "target_id": "vaccination campaign", "strength": 2}, {"source_id": "vaccine hesitancy", "target_id": "mass vaccination campaign", "strength": 2}, {"source_id": "vaccine hesitancy", "target_id": "vaccine characteristics", "strength": 3}, {"source_id": "vaccine acceptance", "target_id": "mass vaccination campaign", "strength": 2}, {"source_id": "vaccination campaign", "target_id": "vaccine acceptance", "strength": 2}, {"source_id": "vaccine refusal", "target_id": "vaccination campaign", "strength": 2}, {"source_id": "herd immunity", "target_id": "vaccination campaign", "strength": 3}, {"source_id": "effects of NPIs", "target_id": "non-pharmaceutical interventions", "strength": 2}, {"source_id": "influenza vaccination coverage", "target_id": "vaccination coverage", "strength": 2}, {"source_id": "vaccine safety", "target_id": "vaccine acceptance", "strength": 2}, {"source_id": "COVID-19 vaccine", "target_id": "vaccination program", "strength": 3}, {"source_id": "vaccination program", "target_id": "vaccine hesitancy", "strength": 4}, {"source_id": "vaccine intentions", "target_id": "COVID-19 vaccine intention", "strength": 4}, {"source_id": "herd immunity", "target_id": "massive vaccination", "strength": 5}, {"source_id": "SARS-CoV-2 infection", "target_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies", "strength": 2}, {"source_id": "health care workers", "target_id": "SARS-CoV-2 antibodies", "strength": 2}, {"source_id": "seroprevalence estimates", "target_id": "health care workers", "strength": 2}, {"source_id": "seroprevalence estimates", "target_id": "cumulative incidence", "strength": 2}, {"source_id": "cumulative incidence", "target_id": "SARS-CoV-2 antibodies", "strength": 2}, {"source_id": "seroprevalence data", "target_id": "cumulative incidence", "strength": 2}, {"source_id": "global burden", "target_id": "health care workers", "strength": 2}, {"source_id": "global burden", "target_id": "seroprevalence data", "strength": 2}, {"source_id": "global burden", "target_id": "systematic review", "strength": 2}, {"source_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies", "target_id": "SARS-CoV-2 infection", "strength": 2}, {"source_id": "systematic review", "target_id": "SARS-CoV-2 antibodies", "strength": 2}, {"source_id": "systematic review", "target_id": "care workers", "strength": 2}, {"source_id": "enzyme-linked immunosorbent assay", "target_id": "SARS-CoV-2", "strength": 3}, {"source_id": "faster virus clearance", "target_id": "viral load", "strength": 2}, {"source_id": "SARS-CoV-2 seroprevalence", "target_id": "SARS-CoV-2 IgG antibodies", "strength": 2}, {"source_id": "COVID-19", "target_id": "years of age", "strength": 2}, {"source_id": "long-term care facilities", "target_id": "care facilities", "strength": 4}, {"source_id": "risk groups", "target_id": "care facilities", "strength": 2}, {"source_id": "care facilities", "target_id": "regular testing", "strength": 2}, {"source_id": "enzyme-linked immunosorbent assay", "target_id": "herd immunity", "strength": 2}, {"source_id": "immune response", "target_id": "transplant recipients", "strength": 2}, {"source_id": "vaccination acceptance", "target_id": "healthcare workers", "strength": 2}, {"source_id": "healthcare workers", "target_id": "vaccination acceptance", "strength": 2}, {"source_id": "healthcare workers", "target_id": "vaccination hesitancy", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "healthcare workers", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "serological tests", "strength": 2}, {"source_id": "vaccine uptake", "target_id": "vaccine hesitancy", "strength": 4}, {"source_id": "vaccine trials", "target_id": "COVID-19 vaccine", "strength": 2}, {"source_id": "infectious (Ct<30) subset", "target_id": "vaccine rollout", "strength": 2}, {"source_id": "vaccine rollout", "target_id": "antigen test", "strength": 2}, {"source_id": "antibody titers", "target_id": "SARS-CoV-2", "strength": 4}, {"source_id": "cellular immunity", "target_id": "SARS-CoV-2 vaccines", "strength": 2}, {"source_id": "population immunity", "target_id": "SARS-CoV-2", "strength": 5}, {"source_id": "metaheuristic algorithms", "target_id": "coronavirus herd immunity optimizer", "strength": 2}, {"source_id": "electricity market data", "target_id": "GDP loss", "strength": 2}, {"source_id": "electricity market data", "target_id": "policy evaluation", "strength": 2}, {"source_id": "macroeconomic indicators", "target_id": "policy evaluation", "strength": 2}, {"source_id": "GDP loss", "target_id": "policy evaluation", "strength": 2}, {"source_id": "herd immunity", "target_id": "antibody response", "strength": 2}, {"source_id": "vaccination intention", "target_id": "vaccine uptake", "strength": 2}, {"source_id": "blood donors", "target_id": "SARS-CoV-2 IgG antibodies", "strength": 2}, {"source_id": "age groups", "target_id": "years age group", "strength": 2}, {"source_id": "COVID-19", "target_id": "immune system", "strength": 2}, {"source_id": "immune system", "target_id": "SARS-CoV-2", "strength": 3}, {"source_id": "COVID-19 vaccine", "target_id": "public health officials", "strength": 2}, {"source_id": "public health officials", "target_id": "COVID-19 vaccine", "strength": 2}, {"source_id": "public health strategies", "target_id": "health strategies", "strength": 3}, {"source_id": "COVID-19 vaccine", "target_id": "COVID-19 vaccination intention", "strength": 3}, {"source_id": "COVID-19", "target_id": "emergency department", "strength": 2}, {"source_id": "SARS-CoV", "target_id": "long-term survival", "strength": 2}, {"source_id": "IgG index values", "target_id": "Delta variant", "strength": 2}, {"source_id": "BNT162b2 vaccination", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "positive externalities", "target_id": "game-theoretic analysis", "strength": 2}, {"source_id": "social norms", "target_id": "Nash equilibrium", "strength": 2}, {"source_id": "game-theoretic approach", "target_id": "social norms", "strength": 2}, {"source_id": "humoral immune response", "target_id": "SARS-CoV-2-specific antibodies", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "cancer patients", "strength": 2}, {"source_id": "side effects", "target_id": "vaccination campaign", "strength": 3}, {"source_id": "COVID-19 vaccine hesitancy", "target_id": "COVID-19 vaccination", "strength": 2}, {"source_id": "SARS-CoV-2 vaccines", "target_id": "immune response", "strength": 2}, {"source_id": "COVID-19 diagnosis", "target_id": "presence of anosmia", "strength": 2}, {"source_id": "COVID-19 diagnosis", "target_id": "more symptoms", "strength": 2}, {"source_id": "COVID-19", "target_id": "positive household contacts", "strength": 2}, {"source_id": "mathematical model", "target_id": "ultrametric model", "strength": 2}, {"source_id": "random walk", "target_id": "mathematical model", "strength": 3}, {"source_id": "SARS-CoV-2 infection", "target_id": "cohort study", "strength": 3}, {"source_id": "cohort study", "target_id": "SARS-CoV-2 antibodies", "strength": 2}, {"source_id": "SARS-CoV-2 infection", "target_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection", "strength": 2}, {"source_id": "first dose", "target_id": "mRNA vaccines", "strength": 2}, {"source_id": "second dose", "target_id": "first dose", "strength": 3}, {"source_id": "SARS-CoV-2", "target_id": "antibody titres", "strength": 2}, {"source_id": "antibody titres", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "herd immunity", "target_id": "mortality rate", "strength": 2}, {"source_id": "herd immunity", "target_id": "severe disease", "strength": 2}, {"source_id": "vaccination hesitancy", "target_id": "herd immunity", "strength": 2}, {"source_id": "herd immunity", "target_id": "vaccination hesitancy", "strength": 2}, {"source_id": "viral infection", "target_id": "herd immunity", "strength": 2}, {"source_id": "economic activity", "target_id": "numerical exercise", "strength": 2}, {"source_id": "policy analysis", "target_id": "numerical exercise", "strength": 2}, {"source_id": "COVID-19 vaccine", "target_id": "COVID-19 vaccine effectiveness", "strength": 2}, {"source_id": "immune response", "target_id": "adaptive immunity", "strength": 2}, {"source_id": "herd immunity", "target_id": "mass vaccination", "strength": 9}, {"source_id": "SARS-CoV-2", "target_id": "Omicron variant", "strength": 3}, {"source_id": "vaccination rates", "target_id": "non-pharmaceutical interventions", "strength": 2}, {"source_id": "vaccine refusal", "target_id": "vaccine acceptance", "strength": 3}, {"source_id": "herd immunity threshold", "target_id": "herd immunity", "strength": 16}, {"source_id": "immunity threshold", "target_id": "vaccination program", "strength": 2}, {"source_id": "vaccination program", "target_id": "immunity threshold", "strength": 2}, {"source_id": "vaccination program", "target_id": "herd immunity", "strength": 9}, {"source_id": "herd immunity", "target_id": "immunity threshold", "strength": 7}, {"source_id": "herd immunity", "target_id": "vaccination rates", "strength": 9}, {"source_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection", "target_id": "SARS-CoV-2", "strength": 5}, {"source_id": "SARS-CoV-2 IgG antibodies", "target_id": "SARS-CoV-2", "strength": 6}, {"source_id": "SARS-CoV-2 IgG antibodies", "target_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection", "strength": 3}, {"source_id": "SARS-CoV-2 IgG antibodies", "target_id": "herd immunity", "strength": 4}, {"source_id": "herd immunity", "target_id": "number of infections", "strength": 2}, {"source_id": "COVID-19 vaccination", "target_id": "vaccine hesitancy", "strength": 10}, {"source_id": "vaccine hesitancy", "target_id": "COVID-19 vaccination", "strength": 10}, {"source_id": "SARS-CoV-2 virus", "target_id": "SARS-CoV-2", "strength": 6}, {"source_id": "SARS-CoV-2", "target_id": "SARS-CoV-2 virus", "strength": 6}, {"source_id": "SARS-CoV-2", "target_id": "immunity threshold", "strength": 4}, {"source_id": "immunity threshold", "target_id": "infection fatality rate", "strength": 2}, {"source_id": "COVID-19 vaccine", "target_id": "vaccination campaign", "strength": 3}, {"source_id": "adverse reactions", "target_id": "vaccine hesitancy", "strength": 2}, {"source_id": "personality trait scores", "target_id": "prosocial nature", "strength": 3}, {"source_id": "different messages", "target_id": "underlying psychological processes", "strength": 2}, {"source_id": "different messages", "target_id": "personality trait scores", "strength": 2}, {"source_id": "COVID-19 vaccination", "target_id": "prosocial traits", "strength": 2}, {"source_id": "immunity threshold", "target_id": "COVID-19", "strength": 4}, {"source_id": "COVID-19", "target_id": "herd immunity threshold", "strength": 4}, {"source_id": "COVID-19", "target_id": "herd immunity", "strength": 18}, {"source_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic", "target_id": "acute respiratory syndrome coronavirus 2 pandemic", "strength": 5}, {"source_id": "acute respiratory syndrome coronavirus 2 pandemic", "target_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic", "strength": 5}, {"source_id": "SARS-CoV-2 vaccination", "target_id": "booster vaccination", "strength": 2}, {"source_id": "severe acute respiratory syndrome coronavirus type 2", "target_id": "SARS-CoV-2 vaccination", "strength": 2}, {"source_id": "healthcare professionals", "target_id": "COVID-19 vaccine", "strength": 2}, {"source_id": "clinical characteristics", "target_id": "IgG antibodies", "strength": 2}, {"source_id": "SARS-CoV-2 epidemic", "target_id": "viral mutations", "strength": 4}, {"source_id": "healthy blood donors", "target_id": "SARS-CoV-2 antibodies", "strength": 3}, {"source_id": "seroprevalence rates", "target_id": "healthy blood donors", "strength": 3}, {"source_id": "herd immunity", "target_id": "blood donors", "strength": 3}, {"source_id": "dynamical equations", "target_id": "network science", "strength": 2}, {"source_id": "COVID-19 pandemic", "target_id": "democracy", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "HLA alleles", "strength": 2}, {"source_id": "SARS-CoV-2 variants", "target_id": "population immunity", "strength": 2}, {"source_id": "population immunity", "target_id": "vaccine-elicited antibodies", "strength": 2}, {"source_id": "COVID-19 infection", "target_id": "COVID-19 cases", "strength": 3}, {"source_id": "number of deaths", "target_id": "mortality rate", "strength": 2}, {"source_id": "COVID-19 vaccine", "target_id": "vaccine uptake", "strength": 7}, {"source_id": "COVID-19 vaccine", "target_id": "side effects", "strength": 11}, {"source_id": "unmet need", "target_id": "side effects", "strength": 2}, {"source_id": "herd immunity", "target_id": "cross-sectional study", "strength": 2}, {"source_id": "incidence rate", "target_id": "COVID-19 infection", "strength": 2}, {"source_id": "herd immunity", "target_id": "World Health Organization", "strength": 2}, {"source_id": "vaccine acceptance", "target_id": "COVID-19 vaccine", "strength": 8}, {"source_id": "World Health Organization", "target_id": "COVID-19", "strength": 2}, {"source_id": "COVID-19", "target_id": "World Health Organization", "strength": 2}, {"source_id": "measles outbreak", "target_id": "immunisation activities", "strength": 2}, {"source_id": "vaccination coverage", "target_id": "measles vaccination coverage", "strength": 2}, {"source_id": "most countries", "target_id": "greater share", "strength": 2}, {"source_id": "welfare losses", "target_id": "most countries", "strength": 2}, {"source_id": "poverty effects", "target_id": "COVID-19 pandemic", "strength": 2}, {"source_id": "poverty accounts", "target_id": "ratio of poverty", "strength": 2}, {"source_id": "poverty accounts", "target_id": "poor countries", "strength": 2}, {"source_id": "agnostic view", "target_id": "greater share", "strength": 2}, {"source_id": "poverty", "target_id": "poor countries", "strength": 2}, {"source_id": "poverty", "target_id": "COVID-19 pandemic", "strength": 2}, {"source_id": "COVID-19 pandemic", "target_id": "most countries", "strength": 3}, {"source_id": "COVID-19 pandemic", "target_id": "welfare consequences", "strength": 2}, {"source_id": "countries", "target_id": "welfare consequences", "strength": 2}, {"source_id": "countries", "target_id": "COVID-19 pandemic", "strength": 4}, {"source_id": "growth estimates", "target_id": "greater share", "strength": 2}, {"source_id": "asymptomatic forms", "target_id": "herd immunity", "strength": 2}, {"source_id": "side effects", "target_id": "second dose", "strength": 2}, {"source_id": "infectious diseases", "target_id": "immunized population", "strength": 4}, {"source_id": "immunized population", "target_id": "herd immunity", "strength": 5}, {"source_id": "immunized population", "target_id": "contact infection", "strength": 4}, {"source_id": "contact infection", "target_id": "immunized population", "strength": 4}, {"source_id": "diffusion equation", "target_id": "adic diffusion equation", "strength": 4}, {"source_id": "diffusion equation", "target_id": "new mathematical model", "strength": 4}, {"source_id": "diffusion equation", "target_id": "statistical physics", "strength": 4}, {"source_id": "diffusion equation", "target_id": "number field", "strength": 4}, {"source_id": "adic diffusion equation", "target_id": "statistical physics", "strength": 4}, {"source_id": "adic diffusion equation", "target_id": "ultrametric spaces", "strength": 4}, {"source_id": "social hierarchy\u2019s levels", "target_id": "ultrametric spaces", "strength": 7}, {"source_id": "new mathematical model", "target_id": "mathematical model", "strength": 5}, {"source_id": "new mathematical model", "target_id": "social hierarchy\u2019s levels", "strength": 4}, {"source_id": "standard mathematical model", "target_id": "social hierarchy\u2019s levels", "strength": 5}, {"source_id": "standard mathematical model", "target_id": "new mathematical model", "strength": 4}, {"source_id": "adic number fields", "target_id": "ultrametric spaces", "strength": 4}, {"source_id": "statistical physics", "target_id": "SIR model", "strength": 4}, {"source_id": "algebraic structure", "target_id": "mathematical model", "strength": 4}, {"source_id": "algebraic structure", "target_id": "new mathematical model", "strength": 4}, {"source_id": "algebraic structure", "target_id": "standard mathematical model", "strength": 4}, {"source_id": "algebraic structure", "target_id": "ultrametric spaces", "strength": 4}, {"source_id": "algebraic structure", "target_id": "number field", "strength": 4}, {"source_id": "ultrametric spaces", "target_id": "number field", "strength": 4}, {"source_id": "number field", "target_id": "social hierarchy\u2019s levels", "strength": 4}, {"source_id": "number field", "target_id": "new mathematical model", "strength": 4}, {"source_id": "number field", "target_id": "ultrametric spaces", "strength": 4}, {"source_id": "SIR model", "target_id": "adic number fields", "strength": 4}, {"source_id": "SIR model", "target_id": "statistical physics", "strength": 4}, {"source_id": "contact infection", "target_id": "susceptible individuals", "strength": 4}, {"source_id": "herd immunity", "target_id": "susceptible individuals", "strength": 8}, {"source_id": "Monte Carlo simulations", "target_id": "Monte Carlo approach", "strength": 2}, {"source_id": "Monte Carlo simulations", "target_id": "deterministic model", "strength": 2}, {"source_id": "numerical solution", "target_id": "Monte Carlo approach", "strength": 2}, {"source_id": "numerical solution", "target_id": "deterministic model", "strength": 2}, {"source_id": "ethical values", "target_id": "ethical dilemmas", "strength": 2}, {"source_id": "COVID-19 pandemic", "target_id": "policy", "strength": 2}, {"source_id": "common good", "target_id": "ethics", "strength": 2}, {"source_id": "policy", "target_id": "health policy", "strength": 2}, {"source_id": "policy", "target_id": "policy makers", "strength": 2}, {"source_id": "alternative policies", "target_id": "policy", "strength": 3}, {"source_id": "mRNA vaccines", "target_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection", "strength": 2}, {"source_id": "adverse reactions", "target_id": "mRNA vaccines", "strength": 2}, {"source_id": "adverse reactions", "target_id": "side effects", "strength": 2}, {"source_id": "existence of hubs", "target_id": "multi-agent systems", "strength": 2}, {"source_id": "mathematical modeling", "target_id": "stochastic multi-agent systems", "strength": 2}, {"source_id": "mathematical modeling", "target_id": "stochastic simulation", "strength": 2}, {"source_id": "epidemic dynamics", "target_id": "ODE model", "strength": 2}, {"source_id": "epidemic dynamics", "target_id": "dynamical evolution", "strength": 2}, {"source_id": "variants of concern", "target_id": "acute respiratory syndrome coronavirus 2 infection", "strength": 2}, {"source_id": "adverse events", "target_id": "variants of concern", "strength": 2}, {"source_id": "immune individuals", "target_id": "susceptible individuals", "strength": 2}, {"source_id": "susceptible individuals", "target_id": "immune individuals", "strength": 2}, {"source_id": "COVID-19 vaccine", "target_id": "cohort study", "strength": 2}, {"source_id": "SARS-CoV-2 infection", "target_id": "SARS-CoV-2", "strength": 11}, {"source_id": "seropositivity rate", "target_id": "COVID-19 infection", "strength": 2}, {"source_id": "T cell responses", "target_id": "cell epitopes", "strength": 2}, {"source_id": "second dose", "target_id": "SARS-CoV-2 infection", "strength": 3}, {"source_id": "second dose", "target_id": "immune response", "strength": 4}, {"source_id": "second dose", "target_id": "BNT162b2 mRNA COVID-19 vaccine", "strength": 2}, {"source_id": "BNT162b2 mRNA COVID-19 vaccine", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "vaccination rates", "target_id": "immunity duration", "strength": 3}, {"source_id": "side effects", "target_id": "COVID-19 vaccine hesitancy", "strength": 2}, {"source_id": "herd immunity", "target_id": "COVID-19 vaccine hesitancy", "strength": 5}, {"source_id": "power-law dynamics", "target_id": "dimensional Euclidean lattice", "strength": 2}, {"source_id": "infectious diseases", "target_id": "susceptible individuals", "strength": 2}, {"source_id": "basic reproduction number", "target_id": "mathematical model", "strength": 2}, {"source_id": "severe acute respiratory syndrome coronavirus 2", "target_id": "acute respiratory syndrome coronavirus 2", "strength": 3}, {"source_id": "severe acute respiratory syndrome coronavirus 2", "target_id": "respiratory syndrome coronavirus 2", "strength": 3}, {"source_id": "acute respiratory syndrome coronavirus 2", "target_id": "severe acute respiratory syndrome coronavirus 2", "strength": 3}, {"source_id": "acute respiratory syndrome coronavirus 2", "target_id": "coronavirus 2", "strength": 3}, {"source_id": "syndrome coronavirus 2", "target_id": "acute respiratory syndrome coronavirus 2", "strength": 3}, {"source_id": "coronavirus 2", "target_id": "severe acute respiratory syndrome coronavirus 2", "strength": 3}, {"source_id": "SARS-CoV-2", "target_id": "clinical trials", "strength": 2}, {"source_id": "clinical trials", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "COVID-19 vaccine", "target_id": "vaccination intention", "strength": 6}, {"source_id": "vaccine effectiveness", "target_id": "COVID-19 vaccine", "strength": 5}, {"source_id": "COVID-19 vaccine", "target_id": "young adults", "strength": 3}, {"source_id": "young adults", "target_id": "COVID-19 vaccine", "strength": 3}, {"source_id": "vaccination program", "target_id": "side effects", "strength": 3}, {"source_id": "random walk", "target_id": "ultrametric spaces", "strength": 4}, {"source_id": "random walk", "target_id": "ultrametric model", "strength": 3}, {"source_id": "ultrametric spaces", "target_id": "COVID-19 dynamics", "strength": 2}, {"source_id": "ultrametric spaces", "target_id": "ultrametric model", "strength": 3}, {"source_id": "COVID-19 dynamics", "target_id": "social hierarchy\u2019s levels", "strength": 2}, {"source_id": "COVID-19 dynamics", "target_id": "ultrametric model", "strength": 2}, {"source_id": "B cells", "target_id": "acute SARS-CoV-2 infection", "strength": 2}, {"source_id": "vaccine efficacy", "target_id": "vaccination rates", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "mass vaccination", "strength": 2}, {"source_id": "global herd immunity", "target_id": "herd immunity", "strength": 3}, {"source_id": "recent SARS-CoV-2 infection", "target_id": "SARS-CoV-2 IgG", "strength": 2}, {"source_id": "recent SARS-CoV-2 infection", "target_id": "seroprevalence study", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "systematic review", "strength": 4}, {"source_id": "SARS-CoV-2 infection", "target_id": "general population", "strength": 5}, {"source_id": "vaccine effectiveness", "target_id": "general population", "strength": 2}, {"source_id": "peptide vaccine", "target_id": "receptor-binding domain", "strength": 2}, {"source_id": "COVID-19 infection", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "mass vaccination campaign", "target_id": "vaccination campaign", "strength": 3}, {"source_id": "herd immunity benefits", "target_id": "vaccine acceptance", "strength": 3}, {"source_id": "vaccine characteristics", "target_id": "mass vaccination campaign", "strength": 2}, {"source_id": "vaccine characteristics", "target_id": "herd immunity benefits", "strength": 2}, {"source_id": "vaccine characteristics", "target_id": "vaccine hesitancy", "strength": 3}, {"source_id": "vaccine characteristics", "target_id": "herd immunity", "strength": 2}, {"source_id": "vaccine hesitancy", "target_id": "herd immunity benefits", "strength": 3}, {"source_id": "vaccination campaign", "target_id": "vaccine refusal", "strength": 2}, {"source_id": "vaccine refusal", "target_id": "vaccine hesitancy", "strength": 2}, {"source_id": "vaccine refusal", "target_id": "herd immunity", "strength": 2}, {"source_id": "herd immunity", "target_id": "vaccine characteristics", "strength": 2}, {"source_id": "vaccine acceptance", "target_id": "vaccine safety", "strength": 2}, {"source_id": "COVID-19 cases", "target_id": "incidence rate", "strength": 2}, {"source_id": "massive vaccination", "target_id": "herd immunity", "strength": 5}, {"source_id": "herd immunity", "target_id": "non-pharmaceutical interventions", "strength": 2}, {"source_id": "SARS-CoV-2 antibodies", "target_id": "general population", "strength": 2}, {"source_id": "general population", "target_id": "SARS-CoV-2 antibodies", "strength": 2}, {"source_id": "SARS-CoV-2 antibodies", "target_id": "seroprevalence estimates", "strength": 2}, {"source_id": "health care workers", "target_id": "SARS-CoV-2 infection", "strength": 3}, {"source_id": "health care workers", "target_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies", "strength": 2}, {"source_id": "global burden", "target_id": "SARS-CoV-2 infection", "strength": 2}, {"source_id": "care workers", "target_id": "SARS-CoV-2 infection", "strength": 2}, {"source_id": "care workers", "target_id": "cumulative incidence", "strength": 2}, {"source_id": "care workers", "target_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies", "strength": 2}, {"source_id": "care workers", "target_id": "systematic review", "strength": 2}, {"source_id": "systematic review", "target_id": "SARS-CoV-2 infection", "strength": 2}, {"source_id": "healthy blood donors", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "vaccination program", "target_id": "vaccination campaign", "strength": 3}, {"source_id": "SARS-CoV-2", "target_id": "distinct symptomatology", "strength": 2}, {"source_id": "SARS-CoV-2 immune response", "target_id": "viral load", "strength": 2}, {"source_id": "SARS-CoV-2 IgG antibodies", "target_id": "SARS-CoV-2 seroprevalence", "strength": 2}, {"source_id": "healthcare workers", "target_id": "vaccine hesitancy", "strength": 2}, {"source_id": "long-term care facilities", "target_id": "number of infections", "strength": 2}, {"source_id": "number of infections", "target_id": "care facilities", "strength": 2}, {"source_id": "COVID-19 vaccine", "target_id": "vaccine trials", "strength": 2}, {"source_id": "mild symptoms", "target_id": "case series", "strength": 2}, {"source_id": "systematic review", "target_id": "case series", "strength": 2}, {"source_id": "antigen test", "target_id": "vaccine rollout", "strength": 2}, {"source_id": "vaccine efficacy", "target_id": "post-exposure prophylaxis", "strength": 2}, {"source_id": "SARS-CoV-2 infection", "target_id": "cellular immunity", "strength": 2}, {"source_id": "SARS-CoV-2 vaccines", "target_id": "SARS-CoV-2", "strength": 4}, {"source_id": "SARS-CoV-2 vaccines", "target_id": "SARS-CoV-2 infection", "strength": 3}, {"source_id": "SARS-CoV-2 vaccines", "target_id": "cellular immunity", "strength": 2}, {"source_id": "cellular immunity", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "systematic review", "target_id": "COVID-19 vaccine", "strength": 2}, {"source_id": "mandatory vaccination", "target_id": "vaccine hesitancy", "strength": 2}, {"source_id": "SARS-CoV-2-specific IgG", "target_id": "SARS-CoV-2", "strength": 3}, {"source_id": "population immunity", "target_id": "SARS-CoV-2-specific IgG", "strength": 2}, {"source_id": "macroeconomic indicators", "target_id": "GDP loss", "strength": 2}, {"source_id": "domestic product", "target_id": "policy evaluation", "strength": 2}, {"source_id": "SARS-CoV-2 infection", "target_id": "antibody response", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "immune system", "strength": 3}, {"source_id": "blood donors", "target_id": "enzyme-linked immunosorbent assay", "strength": 2}, {"source_id": "vaccine intentions", "target_id": "herd immunity", "strength": 3}, {"source_id": "respiratory tract", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "SARS-CoV-2 infection", "target_id": "asymptomatic SARS-CoV-2 infection", "strength": 2}, {"source_id": "COVID-19", "target_id": "vaccination program", "strength": 3}, {"source_id": "immune individuals", "target_id": "herd immunity", "strength": 2}, {"source_id": "IgG index values", "target_id": "antibody titers", "strength": 2}, {"source_id": "first dose", "target_id": "BNT162b2 vaccination", "strength": 2}, {"source_id": "Delta variant", "target_id": "antibody titers", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "side effects", "strength": 2}, {"source_id": "side effects", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "game-theoretic approach", "target_id": "Nash equilibrium", "strength": 2}, {"source_id": "game-theoretic approach", "target_id": "game-theoretic analysis", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "acute respiratory syndrome coronavirus 2 pandemic", "strength": 2}, {"source_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "acute respiratory syndrome coronavirus 2 pandemic", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "SARS-CoV-2-specific antibodies", "target_id": "immune response", "strength": 2}, {"source_id": "fatality rate", "target_id": "infection fatality rate", "strength": 2}, {"source_id": "vaccine uptake", "target_id": "COVID-19 vaccination", "strength": 2}, {"source_id": "side effects", "target_id": "COVID-19", "strength": 2}, {"source_id": "vaccination campaign", "target_id": "side effects", "strength": 3}, {"source_id": "cohort study", "target_id": "retrospective closed cohort study", "strength": 2}, {"source_id": "cohort study", "target_id": "SARS-CoV-2 infection", "strength": 3}, {"source_id": "herd immunity benefits", "target_id": "COVID-19 vaccine hesitancy", "strength": 2}, {"source_id": "SARS-CoV-2 infection", "target_id": "acute respiratory syndrome coronavirus 2 infection", "strength": 2}, {"source_id": "first dose", "target_id": "second dose", "strength": 3}, {"source_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection", "target_id": "SARS-CoV-2 infection", "strength": 2}, {"source_id": "protective immunity", "target_id": "herd immunity", "strength": 2}, {"source_id": "severe disease", "target_id": "herd immunity", "strength": 2}, {"source_id": "vaccination strategies", "target_id": "vaccine hesitancy", "strength": 2}, {"source_id": "COVID-19 vaccination", "target_id": "vaccination campaign", "strength": 3}, {"source_id": "policy analysis", "target_id": "policy", "strength": 2}, {"source_id": "vaccine effectiveness", "target_id": "COVID-19 vaccine effectiveness", "strength": 2}, {"source_id": "adaptive immunity", "target_id": "immune response", "strength": 2}, {"source_id": "Omicron variant", "target_id": "Delta variant", "strength": 3}, {"source_id": "World Health Organization", "target_id": "COVID-19 vaccine", "strength": 3}, {"source_id": "COVID-19 vaccine acceptance", "target_id": "vaccine acceptance", "strength": 9}, {"source_id": "vaccine acceptance", "target_id": "COVID-19 vaccine acceptance", "strength": 9}, {"source_id": "herd immunity threshold", "target_id": "immunity threshold", "strength": 20}, {"source_id": "herd immunity threshold", "target_id": "vaccination rates", "strength": 5}, {"source_id": "SARS-CoV-2", "target_id": "acute respiratory syndrome coronavirus 2 infection", "strength": 5}, {"source_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection", "target_id": "acute respiratory syndrome coronavirus 2 infection", "strength": 21}, {"source_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection", "target_id": "SARS-CoV-2 IgG antibodies", "strength": 3}, {"source_id": "herd immunity", "target_id": "SARS-CoV-2", "strength": 42}, {"source_id": "herd immunity", "target_id": "SARS-CoV-2 virus", "strength": 4}, {"source_id": "SARS-CoV-2", "target_id": "herd immunity threshold", "strength": 5}, {"source_id": "vaccine hesitancy", "target_id": "COVID-19 vaccine hesitancy", "strength": 22}, {"source_id": "World Health Organization", "target_id": "vaccine hesitancy", "strength": 2}, {"source_id": "vaccination campaign", "target_id": "COVID-19 vaccine", "strength": 3}, {"source_id": "underlying psychological processes", "target_id": "COVID-19 vaccination", "strength": 3}, {"source_id": "young people", "target_id": "personality trait scores", "strength": 3}, {"source_id": "COVID-19 vaccination", "target_id": "personality trait scores", "strength": 3}, {"source_id": "herd immunity", "target_id": "COVID-19", "strength": 18}, {"source_id": "benchmark datasets", "target_id": "classification accuracy", "strength": 2}, {"source_id": "neural network", "target_id": "coronavirus herd immunity optimizer", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "COVID-19 vaccine", "strength": 5}, {"source_id": "SARS-CoV-2", "target_id": "severe disease", "strength": 2}, {"source_id": "booster vaccination", "target_id": "SARS-CoV-2 vaccination", "strength": 2}, {"source_id": "acute respiratory syndrome coronavirus 2 infection", "target_id": "IgG antibodies", "strength": 3}, {"source_id": "population immunity", "target_id": "SARS-CoV-2 virus", "strength": 3}, {"source_id": "SARS-CoV-2 infection", "target_id": "cumulative incidence", "strength": 3}, {"source_id": "SARS-CoV-2 infection", "target_id": "herd immunity", "strength": 8}, {"source_id": "COVID-19 infection", "target_id": "IgG antibodies", "strength": 2}, {"source_id": "herd immunity", "target_id": "effective vaccine", "strength": 3}, {"source_id": "vaccination intention", "target_id": "COVID-19", "strength": 2}, {"source_id": "effective vaccine", "target_id": "vaccination intention", "strength": 2}, {"source_id": "blood donors", "target_id": "healthy blood donors", "strength": 6}, {"source_id": "SARS-CoV-2 antibodies", "target_id": "IgG antibodies", "strength": 5}, {"source_id": "SARS-CoV-2 antibodies", "target_id": "herd immunity", "strength": 5}, {"source_id": "new dynamical equations", "target_id": "network science", "strength": 2}, {"source_id": "dynamical equations", "target_id": "epidemic model", "strength": 2}, {"source_id": "epidemic model", "target_id": "SIR model", "strength": 3}, {"source_id": "network science", "target_id": "new dynamical equations", "strength": 2}, {"source_id": "herd immunity", "target_id": "acute respiratory distress syndrome", "strength": 2}, {"source_id": "antibody response", "target_id": "SARS-CoV-2", "strength": 5}, {"source_id": "SARS-CoV-2 variants", "target_id": "vaccine-elicited antibodies", "strength": 2}, {"source_id": "SARS-CoV-2 variants", "target_id": "US population", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "vaccination coverage", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "vaccine hesitancy", "strength": 2}, {"source_id": "vaccine hesitancy", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "vaccination program", "target_id": "Delta variant", "strength": 2}, {"source_id": "Delta variant", "target_id": "vaccination program", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "mortality rate", "strength": 2}, {"source_id": "COVID-19 infection", "target_id": "COVID-19 vaccination", "strength": 3}, {"source_id": "cross-sectional study", "target_id": "COVID-19 vaccine", "strength": 4}, {"source_id": "cross-sectional study", "target_id": "online cross-sectional study", "strength": 2}, {"source_id": "cross-sectional study", "target_id": "vaccine uptake", "strength": 2}, {"source_id": "side effects", "target_id": "cross-sectional study", "strength": 3}, {"source_id": "side effects", "target_id": "vaccine uptake", "strength": 2}, {"source_id": "COVID-19 infection", "target_id": "prior infection", "strength": 2}, {"source_id": "incidence rate", "target_id": "COVID-19 reinfection", "strength": 2}, {"source_id": "herd immunity", "target_id": "viral load", "strength": 2}, {"source_id": "asymptomatic infection", "target_id": "asymptomatic cases", "strength": 2}, {"source_id": "herd immunity", "target_id": "vaccine acceptance", "strength": 4}, {"source_id": "COVID-19 vaccine uptake", "target_id": "COVID-19 vaccine", "strength": 2}, {"source_id": "vaccine uptake", "target_id": "COVID-19 vaccine uptake", "strength": 3}, {"source_id": "vaccination coverage", "target_id": "immunisation activities", "strength": 2}, {"source_id": "population immunity", "target_id": "measles outbreak", "strength": 2}, {"source_id": "most countries", "target_id": "COVID-19 pandemic", "strength": 3}, {"source_id": "most countries", "target_id": "countries", "strength": 3}, {"source_id": "welfare losses", "target_id": "welfare consequences", "strength": 2}, {"source_id": "welfare losses", "target_id": "poor countries", "strength": 2}, {"source_id": "poverty effects", "target_id": "ratio of poverty", "strength": 2}, {"source_id": "poverty effects", "target_id": "growth estimates", "strength": 2}, {"source_id": "COVID-19 pandemic", "target_id": "poor countries", "strength": 2}, {"source_id": "countries", "target_id": "greater share", "strength": 2}, {"source_id": "growth estimates", "target_id": "COVID-19 pandemic", "strength": 2}, {"source_id": "IgG antibodies", "target_id": "herd immunity", "strength": 3}, {"source_id": "surrogate virus neutralization test", "target_id": "SARS-CoV-2 surrogate virus neutralization test", "strength": 2}, {"source_id": "herd immunity threshold", "target_id": "immunized population", "strength": 4}, {"source_id": "contact infection", "target_id": "herd immunity", "strength": 8}, {"source_id": "mathematical model", "target_id": "new mathematical model", "strength": 5}, {"source_id": "mathematical model", "target_id": "statistical physics", "strength": 5}, {"source_id": "mathematical model", "target_id": "algebraic structure", "strength": 4}, {"source_id": "diffusion equation", "target_id": "social hierarchy\u2019s levels", "strength": 4}, {"source_id": "adic diffusion equation", "target_id": "diffusion equation", "strength": 4}, {"source_id": "adic diffusion equation", "target_id": "standard mathematical model", "strength": 4}, {"source_id": "social hierarchy\u2019s levels", "target_id": "diffusion equation", "strength": 4}, {"source_id": "social hierarchy\u2019s levels", "target_id": "new mathematical model", "strength": 4}, {"source_id": "social hierarchy\u2019s levels", "target_id": "algebraic structure", "strength": 4}, {"source_id": "social hierarchy\u2019s levels", "target_id": "number field", "strength": 4}, {"source_id": "social hierarchy\u2019s levels", "target_id": "SIR model", "strength": 6}, {"source_id": "new mathematical model", "target_id": "statistical physics", "strength": 4}, {"source_id": "new mathematical model", "target_id": "SIR model", "strength": 5}, {"source_id": "standard mathematical model", "target_id": "number field", "strength": 4}, {"source_id": "adic number fields", "target_id": "diffusion equation", "strength": 4}, {"source_id": "adic number fields", "target_id": "adic diffusion equation", "strength": 4}, {"source_id": "statistical physics", "target_id": "social hierarchy\u2019s levels", "strength": 5}, {"source_id": "statistical physics", "target_id": "algebraic structure", "strength": 4}, {"source_id": "statistical physics", "target_id": "ultrametric spaces", "strength": 5}, {"source_id": "algebraic structure", "target_id": "adic number fields", "strength": 4}, {"source_id": "ultrametric spaces", "target_id": "social hierarchy\u2019s levels", "strength": 7}, {"source_id": "SIR model", "target_id": "algebraic structure", "strength": 4}, {"source_id": "SIR model", "target_id": "number field", "strength": 4}, {"source_id": "antibody-dependent enhancement", "target_id": "herd immunity", "strength": 2}, {"source_id": "ordinary differential equations", "target_id": "differential equations", "strength": 2}, {"source_id": "Monte Carlo simulations", "target_id": "numerical solution", "strength": 2}, {"source_id": "numerical solution", "target_id": "stochastic process", "strength": 2}, {"source_id": "citizens", "target_id": "institutions", "strength": 2}, {"source_id": "moral obligation", "target_id": "ethics", "strength": 2}, {"source_id": "Sputnik V", "target_id": "COVID-19 vaccine", "strength": 2}, {"source_id": "mRNA vaccines", "target_id": "acute respiratory syndrome coronavirus 2 infection", "strength": 2}, {"source_id": "side effects", "target_id": "adverse reactions", "strength": 2}, {"source_id": "existence of hubs", "target_id": "dynamical evolution", "strength": 2}, {"source_id": "dynamical evolution", "target_id": "stochastic multi-agent systems", "strength": 2}, {"source_id": "dynamical evolution", "target_id": "mathematical modeling", "strength": 3}, {"source_id": "dynamical evolution", "target_id": "point estimates", "strength": 2}, {"source_id": "dynamical evolution", "target_id": "multi-agent systems", "strength": 2}, {"source_id": "mathematical modeling", "target_id": "epidemic dynamics", "strength": 2}, {"source_id": "epidemic dynamics", "target_id": "multi-agent systems", "strength": 2}, {"source_id": "COVID-19 vaccine", "target_id": "variants of concern", "strength": 4}, {"source_id": "emergency use authorization", "target_id": "acute respiratory syndrome coronavirus 2 infection", "strength": 2}, {"source_id": "clinical trials", "target_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection", "strength": 2}, {"source_id": "cohort study", "target_id": "COVID-19 vaccine", "strength": 2}, {"source_id": "cross-sectional study", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "vaccination program", "target_id": "COVID-19 vaccination program", "strength": 4}, {"source_id": "SARS-CoV-2", "target_id": "receptor-binding domain", "strength": 4}, {"source_id": "herd immunity", "target_id": "herd immunity levels", "strength": 2}, {"source_id": "SARS-CoV-2 T-cell response", "target_id": "antibody response", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "T cells", "strength": 5}, {"source_id": "herd immunity", "target_id": "T cells", "strength": 2}, {"source_id": "T cells", "target_id": "herd immunity", "strength": 2}, {"source_id": "BNT162b2 mRNA COVID-19 vaccine", "target_id": "second dose", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "adverse events", "strength": 3}, {"source_id": "seroprevalence rates", "target_id": "SARS-CoV-2", "strength": 3}, {"source_id": "COVID-19 vaccine hesitancy", "target_id": "herd immunity", "strength": 5}, {"source_id": "SARS-CoV-2", "target_id": "viral load", "strength": 3}, {"source_id": "power-law dynamics", "target_id": "regular graphs", "strength": 2}, {"source_id": "topological dimension", "target_id": "dimensional Euclidean lattice", "strength": 2}, {"source_id": "mathematical model", "target_id": "basic reproduction number", "strength": 2}, {"source_id": "respiratory syndrome coronavirus 2", "target_id": "syndrome coronavirus 2", "strength": 3}, {"source_id": "respiratory syndrome coronavirus 2", "target_id": "coronavirus 2", "strength": 3}, {"source_id": "syndrome coronavirus 2", "target_id": "coronavirus 2", "strength": 3}, {"source_id": "Middle East respiratory syndrome", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "Middle East respiratory syndrome", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "vaccine development", "strength": 2}, {"source_id": "clinical trials", "target_id": "vaccine development", "strength": 2}, {"source_id": "SARS-CoV-2 antibodies", "target_id": "seroprevalence data", "strength": 3}, {"source_id": "seroprevalence data", "target_id": "SARS-CoV-2 antibodies", "strength": 3}, {"source_id": "COVID-19 patients", "target_id": "symptom onset", "strength": 2}, {"source_id": "social hierarchy\u2019s levels", "target_id": "random walk", "strength": 3}, {"source_id": "social hierarchy\u2019s levels", "target_id": "ultrametric model", "strength": 2}, {"source_id": "ultrametric spaces", "target_id": "random walk", "strength": 4}, {"source_id": "COVID-19 dynamics", "target_id": "SIR model", "strength": 2}, {"source_id": "developed theory", "target_id": "ultrametric model", "strength": 2}, {"source_id": "ultrametric model", "target_id": "random walk", "strength": 3}, {"source_id": "ultrametric model", "target_id": "COVID-19 dynamics", "strength": 2}, {"source_id": "SIR model", "target_id": "random walk", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "SARS-CoV", "strength": 3}, {"source_id": "vaccine efficacy", "target_id": "vaccination program", "strength": 3}, {"source_id": "IgG antibodies", "target_id": "SARS-CoV2", "strength": 2}, {"source_id": "immune cells", "target_id": "herd immunity", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "global herd immunity", "strength": 2}, {"source_id": "SARS-CoV-2 infection", "target_id": "previous SARS-CoV-2 infection", "strength": 2}, {"source_id": "herd immunity", "target_id": "COVID-19 cases", "strength": 6}, {"source_id": "herd immunity", "target_id": "SARS-CoV-2 immunoglobulin G", "strength": 2}, {"source_id": "mortality rate", "target_id": "infection exposure", "strength": 2}, {"source_id": "hospitalization rates", "target_id": "mortality rate", "strength": 2}, {"source_id": "SARS-CoV-2 IgG", "target_id": "recent SARS-CoV-2 infection", "strength": 2}, {"source_id": "seroprevalence study", "target_id": "SARS-CoV-2 IgG", "strength": 3}, {"source_id": "seroprevalence study", "target_id": "IgG antibodies", "strength": 2}, {"source_id": "systematic review", "target_id": "health care workers", "strength": 3}, {"source_id": "non-human primates", "target_id": "novel SARS-CoV-2 vaccines", "strength": 2}, {"source_id": "receptor-binding domain", "target_id": "peptide vaccine", "strength": 2}, {"source_id": "COVID-19 vaccination", "target_id": "adverse events", "strength": 2}, {"source_id": "adverse events", "target_id": "COVID-19 vaccination", "strength": 2}, {"source_id": "immune response", "target_id": "cellular immune responses", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "humoral response", "strength": 3}, {"source_id": "vaccine hesitancy", "target_id": "vaccination hesitancy", "strength": 3}, {"source_id": "COVID-19 infection", "target_id": "cross-sectional study", "strength": 2}, {"source_id": "mass vaccination campaign", "target_id": "herd immunity benefits", "strength": 2}, {"source_id": "herd immunity benefits", "target_id": "vaccine hesitancy", "strength": 3}, {"source_id": "vaccine characteristics", "target_id": "vaccine refusal", "strength": 2}, {"source_id": "vaccination campaign", "target_id": "mass vaccination campaign", "strength": 3}, {"source_id": "vaccine refusal", "target_id": "vaccine characteristics", "strength": 2}, {"source_id": "herd immunity", "target_id": "mass vaccination campaign", "strength": 2}, {"source_id": "effects of NPIs", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "non-pharmaceutical interventions", "strength": 4}, {"source_id": "SARS-CoV-2", "target_id": "SARS-CoV-2 IgG antibody test", "strength": 2}, {"source_id": "vaccine hesitancy", "target_id": "cross-sectional study", "strength": 2}, {"source_id": "vaccine hesitancy", "target_id": "vaccination program", "strength": 4}, {"source_id": "vaccination program", "target_id": "COVID-19 vaccine", "strength": 3}, {"source_id": "second dose", "target_id": "booster dose", "strength": 2}, {"source_id": "herd immunity", "target_id": "vaccination strategies", "strength": 6}, {"source_id": "vaccination strategies", "target_id": "herd immunity", "strength": 6}, {"source_id": "SARS-CoV-2 antibodies", "target_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies", "strength": 2}, {"source_id": "SARS-CoV-2 infection", "target_id": "seroprevalence estimates", "strength": 2}, {"source_id": "health care workers", "target_id": "cumulative incidence", "strength": 2}, {"source_id": "seroprevalence estimates", "target_id": "care workers", "strength": 2}, {"source_id": "seroprevalence data", "target_id": "SARS-CoV-2 infection", "strength": 2}, {"source_id": "seroprevalence data", "target_id": "care workers", "strength": 2}, {"source_id": "seroprevalence data", "target_id": "systematic review", "strength": 2}, {"source_id": "global burden", "target_id": "seroprevalence estimates", "strength": 2}, {"source_id": "global burden", "target_id": "cumulative incidence", "strength": 2}, {"source_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies", "target_id": "seroprevalence estimates", "strength": 2}, {"source_id": "care workers", "target_id": "SARS-CoV-2 antibodies", "strength": 2}, {"source_id": "systematic review", "target_id": "seroprevalence estimates", "strength": 2}, {"source_id": "systematic review", "target_id": "seroprevalence data", "strength": 2}, {"source_id": "systematic review", "target_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "SARS-CoV-2 immune response", "strength": 2}, {"source_id": "faster virus clearance", "target_id": "SARS-CoV-2 immune response", "strength": 2}, {"source_id": "herd immunity", "target_id": "Omicron variant", "strength": 2}, {"source_id": "COVID-19 vaccination", "target_id": "healthcare workers", "strength": 2}, {"source_id": "transplant recipients", "target_id": "immune response", "strength": 2}, {"source_id": "immunization levels", "target_id": "vaccination program", "strength": 2}, {"source_id": "mild symptoms", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "asymptomatic presentation", "target_id": "antigen test", "strength": 2}, {"source_id": "asymptomatic presentation", "target_id": "vaccine rollout", "strength": 2}, {"source_id": "vaccine rollout", "target_id": "Medical Center", "strength": 2}, {"source_id": "angiotensin-converting enzyme 2", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "antibody titers", "strength": 4}, {"source_id": "infection fatality ratio", "target_id": "fatality ratio", "strength": 2}, {"source_id": "post-exposure prophylaxis", "target_id": "vaccine efficacy", "strength": 2}, {"source_id": "post-exposure prophylaxis", "target_id": "herd immunity", "strength": 2}, {"source_id": "post-exposure prophylaxis", "target_id": "vaccination strategies", "strength": 2}, {"source_id": "vaccine efficacy", "target_id": "vaccination strategies", "strength": 2}, {"source_id": "mass vaccination", "target_id": "vaccination strategies", "strength": 2}, {"source_id": "vaccination strategies", "target_id": "vaccine efficacy", "strength": 2}, {"source_id": "COVID-19 vaccine", "target_id": "systematic review", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "SARS-CoV-2-specific IgG", "strength": 3}, {"source_id": "antibody response", "target_id": "herd immunity", "strength": 2}, {"source_id": "vaccination intention", "target_id": "side effects", "strength": 2}, {"source_id": "SARS-CoV-2 IgG antibodies", "target_id": "blood donors", "strength": 2}, {"source_id": "immune system", "target_id": "COVID-19", "strength": 2}, {"source_id": "blood donors", "target_id": "high-throughput serological assays", "strength": 2}, {"source_id": "New York City metropolitan area", "target_id": "blood donors", "strength": 2}, {"source_id": "health strategies", "target_id": "public health strategies", "strength": 3}, {"source_id": "COVID-19 vaccination intention", "target_id": "COVID-19 vaccine", "strength": 3}, {"source_id": "COVID-19 vaccination intention", "target_id": "vaccine hesitancy", "strength": 2}, {"source_id": "cross-sectional study", "target_id": "vaccine acceptance", "strength": 2}, {"source_id": "IgG index values", "target_id": "first dose", "strength": 2}, {"source_id": "IgG index values", "target_id": "BNT162b2 vaccination", "strength": 2}, {"source_id": "BNT162b2 vaccination", "target_id": "antibody titers", "strength": 2}, {"source_id": "BNT162b2 vaccination", "target_id": "Delta variant", "strength": 2}, {"source_id": "antibody titers", "target_id": "Delta variant", "strength": 2}, {"source_id": "cross-sectional survey", "target_id": "COVID-19 vaccine", "strength": 2}, {"source_id": "free-rider problem", "target_id": "Nash equilibrium", "strength": 2}, {"source_id": "free-rider problem", "target_id": "game-theoretic analysis", "strength": 2}, {"source_id": "game-theoretic approach", "target_id": "non-cooperative solution", "strength": 2}, {"source_id": "vaccine efficacy", "target_id": "COVID-19", "strength": 2}, {"source_id": "SARS-CoV-2 infection", "target_id": "COVID-19 vaccine", "strength": 2}, {"source_id": "T cells", "target_id": "SARS-CoV-2 subunit vaccine", "strength": 2}, {"source_id": "infection fatality rate", "target_id": "fatality rate", "strength": 2}, {"source_id": "COVID-19 diagnosis", "target_id": "COVID-19", "strength": 2}, {"source_id": "ultrametric model", "target_id": "mathematical model", "strength": 2}, {"source_id": "logistic regression analysis", "target_id": "COVID-19 vaccine", "strength": 2}, {"source_id": "SARS-CoV-2 infection", "target_id": "retrospective closed cohort study", "strength": 2}, {"source_id": "closed cohort study", "target_id": "SARS-CoV-2 infection", "strength": 2}, {"source_id": "closed cohort study", "target_id": "cohort study", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "antiviral drugs", "strength": 2}, {"source_id": "COVID-19 patients", "target_id": "COVID-19", "strength": 2}, {"source_id": "herd immunity", "target_id": "protective immunity", "strength": 2}, {"source_id": "COVID-19 patients", "target_id": "immune response", "strength": 3}, {"source_id": "immune response", "target_id": "COVID-19 patients", "strength": 3}, {"source_id": "policy analysis", "target_id": "economic activity", "strength": 2}, {"source_id": "policy", "target_id": "policy analysis", "strength": 2}, {"source_id": "Delta variant", "target_id": "COVID-19 vaccine", "strength": 2}, {"source_id": "SARS-CoV-2-specific IgG antibodies", "target_id": "memory lymphocytes", "strength": 2}, {"source_id": "herd immunity", "target_id": "side effects", "strength": 5}, {"source_id": "immunity threshold", "target_id": "herd immunity threshold", "strength": 20}, {"source_id": "SARS-CoV-2", "target_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection", "strength": 5}, {"source_id": "acute respiratory syndrome coronavirus 2 infection", "target_id": "herd immunity", "strength": 4}, {"source_id": "herd immunity", "target_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection", "strength": 4}, {"source_id": "number of infections", "target_id": "herd immunity", "strength": 2}, {"source_id": "past infection", "target_id": "SARS-CoV-2 infection", "strength": 2}, {"source_id": "infection fatality rate", "target_id": "immunity threshold", "strength": 2}, {"source_id": "immunity threshold", "target_id": "SARS-CoV-2", "strength": 4}, {"source_id": "COVID-19 vaccine", "target_id": "vaccine hesitancy", "strength": 22}, {"source_id": "vaccine hesitancy", "target_id": "cross-sectional survey", "strength": 3}, {"source_id": "COVID-19 vaccine hesitancy", "target_id": "COVID-19 vaccine", "strength": 10}, {"source_id": "COVID-19 vaccine", "target_id": "COVID-19 vaccine hesitancy", "strength": 10}, {"source_id": "prosocial nature", "target_id": "young people", "strength": 3}, {"source_id": "prosocial nature", "target_id": "personality trait scores", "strength": 3}, {"source_id": "different messages", "target_id": "COVID-19 vaccination", "strength": 2}, {"source_id": "COVID-19 vaccination", "target_id": "young people", "strength": 3}, {"source_id": "coronavirus herd immunity optimizer", "target_id": "optimization algorithm", "strength": 3}, {"source_id": "particle swarm optimization", "target_id": "optimization algorithm", "strength": 2}, {"source_id": "benchmark datasets", "target_id": "coronavirus herd immunity optimizer", "strength": 2}, {"source_id": "COVID-19 vaccine", "target_id": "SARS-CoV-2", "strength": 5}, {"source_id": "clinical trials", "target_id": "vaccine candidates", "strength": 3}, {"source_id": "vaccine candidates", "target_id": "clinical trials", "strength": 3}, {"source_id": "SARS-CoV-2", "target_id": "booster vaccination", "strength": 2}, {"source_id": "SARS-CoV-2 vaccination", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "severe acute respiratory syndrome coronavirus type 2", "target_id": "booster vaccination", "strength": 2}, {"source_id": "cumulative incidence", "target_id": "SARS-CoV-2 infection", "strength": 3}, {"source_id": "SARS-CoV-2 antibody seroprevalence", "target_id": "SARS-CoV-2 antibodies", "strength": 2}, {"source_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic", "target_id": "PCR positivity", "strength": 3}, {"source_id": "effective vaccine", "target_id": "COVID-19", "strength": 2}, {"source_id": "clinical characteristics", "target_id": "SARS-CoV-2 antibodies", "strength": 2}, {"source_id": "SARS-CoV-2 antibodies", "target_id": "healthy blood donors", "strength": 3}, {"source_id": "SARS-CoV-2 antibodies", "target_id": "seroprevalence rates", "strength": 3}, {"source_id": "seroprevalence rates", "target_id": "blood donors", "strength": 3}, {"source_id": "new dynamical equations", "target_id": "epidemic model", "strength": 2}, {"source_id": "deterministic epidemic model", "target_id": "epidemic model", "strength": 2}, {"source_id": "deterministic epidemic model", "target_id": "SIR model", "strength": 2}, {"source_id": "dynamical equations", "target_id": "new dynamical equations", "strength": 2}, {"source_id": "SIR equations", "target_id": "epidemic model", "strength": 2}, {"source_id": "SIR equations", "target_id": "SIR model", "strength": 2}, {"source_id": "SIR equations", "target_id": "network science", "strength": 2}, {"source_id": "SIR model", "target_id": "epidemic model", "strength": 3}, {"source_id": "network science", "target_id": "SIR model", "strength": 2}, {"source_id": "democracy", "target_id": "COVID-19 pandemic", "strength": 2}, {"source_id": "acute respiratory distress syndrome", "target_id": "herd immunity", "strength": 2}, {"source_id": "SARS-CoV-2 variants", "target_id": "vaccine-induced immunity", "strength": 3}, {"source_id": "vaccine-induced immunity", "target_id": "SARS-CoV-2 variants", "strength": 3}, {"source_id": "population immunity", "target_id": "mRNA vaccine recipients", "strength": 2}, {"source_id": "new SARS-CoV-2 variants", "target_id": "US population", "strength": 2}, {"source_id": "mortality rate", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "COVID-19 vaccination", "target_id": "herd immunity", "strength": 6}, {"source_id": "vaccine hesitancy", "target_id": "herd immunity", "strength": 10}, {"source_id": "herd immunity", "target_id": "COVID-19 vaccination", "strength": 6}, {"source_id": "herd immunity", "target_id": "vaccine hesitancy", "strength": 10}, {"source_id": "herd immunity", "target_id": "vaccination coverage", "strength": 5}, {"source_id": "SARS-CoV-2 pandemic", "target_id": "COVID-19 vaccine", "strength": 2}, {"source_id": "mass vaccination", "target_id": "vaccine efficacy", "strength": 3}, {"source_id": "viral infection", "target_id": "SARS-CoV-2", "strength": 3}, {"source_id": "COVID-19 vaccine", "target_id": "online cross-sectional study", "strength": 2}, {"source_id": "COVID-19 vaccine", "target_id": "cross-sectional study", "strength": 4}, {"source_id": "vaccine uptake", "target_id": "herd immunity", "strength": 5}, {"source_id": "unmet need", "target_id": "vaccine uptake", "strength": 2}, {"source_id": "unmet need", "target_id": "herd immunity", "strength": 2}, {"source_id": "prior infection", "target_id": "incidence rate", "strength": 2}, {"source_id": "World Health Organization", "target_id": "herd immunity", "strength": 2}, {"source_id": "viral load", "target_id": "herd immunity", "strength": 2}, {"source_id": "vaccination acceptance", "target_id": "COVID-19 vaccination acceptance", "strength": 2}, {"source_id": "COVID-19 vaccine uptake", "target_id": "vaccine uptake", "strength": 3}, {"source_id": "COVID-19 vaccine", "target_id": "COVID-19 vaccine uptake", "strength": 2}, {"source_id": "vaccination coverage", "target_id": "population immunity", "strength": 2}, {"source_id": "population immunity", "target_id": "immunisation activities", "strength": 2}, {"source_id": "welfare costs", "target_id": "most countries", "strength": 2}, {"source_id": "welfare costs", "target_id": "countries", "strength": 2}, {"source_id": "welfare losses", "target_id": "greater share", "strength": 2}, {"source_id": "welfare losses", "target_id": "COVID-19 pandemic", "strength": 2}, {"source_id": "poverty effects", "target_id": "welfare consequences", "strength": 2}, {"source_id": "poverty effects", "target_id": "countries", "strength": 2}, {"source_id": "poverty accounts", "target_id": "agnostic view", "strength": 2}, {"source_id": "agnostic view", "target_id": "growth estimates", "strength": 2}, {"source_id": "poverty", "target_id": "agnostic view", "strength": 2}, {"source_id": "COVID-19 pandemic", "target_id": "growth estimates", "strength": 2}, {"source_id": "growth estimates", "target_id": "most countries", "strength": 2}, {"source_id": "asymptomatic forms", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "surrogate virus neutralization test", "target_id": "neutralization test", "strength": 3}, {"source_id": "neutralization test", "target_id": "surrogate virus neutralization test", "strength": 3}, {"source_id": "herd immunity threshold", "target_id": "infectious diseases", "strength": 5}, {"source_id": "infectious diseases", "target_id": "herd immunity threshold", "strength": 5}, {"source_id": "infectious diseases", "target_id": "vaccination rates", "strength": 4}, {"source_id": "infectious diseases", "target_id": "contact infection", "strength": 6}, {"source_id": "herd immunity", "target_id": "immunized population", "strength": 5}, {"source_id": "herd immunity", "target_id": "contact infection", "strength": 8}, {"source_id": "vaccination rates", "target_id": "immunized population", "strength": 4}, {"source_id": "vaccination rates", "target_id": "contact infection", "strength": 4}, {"source_id": "mathematical model", "target_id": "social hierarchy\u2019s levels", "strength": 6}, {"source_id": "mathematical model", "target_id": "SIR model", "strength": 7}, {"source_id": "diffusion equation", "target_id": "mathematical model", "strength": 4}, {"source_id": "adic diffusion equation", "target_id": "social hierarchy\u2019s levels", "strength": 4}, {"source_id": "social hierarchy\u2019s levels", "target_id": "adic diffusion equation", "strength": 4}, {"source_id": "social hierarchy\u2019s levels", "target_id": "statistical physics", "strength": 5}, {"source_id": "standard mathematical model", "target_id": "adic diffusion equation", "strength": 4}, {"source_id": "standard mathematical model", "target_id": "statistical physics", "strength": 4}, {"source_id": "adic number fields", "target_id": "standard mathematical model", "strength": 4}, {"source_id": "adic number fields", "target_id": "statistical physics", "strength": 4}, {"source_id": "algebraic structure", "target_id": "statistical physics", "strength": 4}, {"source_id": "ultrametric spaces", "target_id": "new mathematical model", "strength": 4}, {"source_id": "ultrametric spaces", "target_id": "standard mathematical model", "strength": 5}, {"source_id": "ultrametric spaces", "target_id": "adic number fields", "strength": 4}, {"source_id": "ultrametric spaces", "target_id": "statistical physics", "strength": 5}, {"source_id": "SIR model", "target_id": "social hierarchy\u2019s levels", "strength": 6}, {"source_id": "SIR model", "target_id": "ultrametric spaces", "strength": 6}, {"source_id": "ethical values", "target_id": "justice", "strength": 2}, {"source_id": "mandatory vaccination policies", "target_id": "ethics", "strength": 2}, {"source_id": "justice", "target_id": "moral obligation", "strength": 2}, {"source_id": "COVID-19 vaccine", "target_id": "acute respiratory syndrome coronavirus 2 infection", "strength": 4}, {"source_id": "Sputnik V", "target_id": "mRNA vaccines", "strength": 2}, {"source_id": "Sputnik V", "target_id": "side effects", "strength": 2}, {"source_id": "mRNA vaccines", "target_id": "COVID-19 vaccine", "strength": 3}, {"source_id": "mRNA vaccines", "target_id": "side effects", "strength": 3}, {"source_id": "side effects", "target_id": "Sputnik V", "strength": 2}, {"source_id": "existence of hubs", "target_id": "stochastic multi-agent systems", "strength": 2}, {"source_id": "existence of hubs", "target_id": "stochastic simulation", "strength": 2}, {"source_id": "epidemic dynamics", "target_id": "stochastic multi-agent systems", "strength": 2}, {"source_id": "COVID-19 vaccine", "target_id": "clinical trials", "strength": 4}, {"source_id": "variants of concern", "target_id": "adverse events", "strength": 2}, {"source_id": "clinical trials", "target_id": "acute respiratory syndrome coronavirus 2 infection", "strength": 2}, {"source_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection", "target_id": "clinical trials", "strength": 2}, {"source_id": "acute respiratory syndrome coronavirus 2 infection", "target_id": "emergency use authorization", "strength": 2}, {"source_id": "acute respiratory syndrome coronavirus 2 infection", "target_id": "variants of concern", "strength": 2}, {"source_id": "acute respiratory syndrome coronavirus 2 infection", "target_id": "clinical trials", "strength": 2}, {"source_id": "herd immunity", "target_id": "clinical trials", "strength": 3}, {"source_id": "healthcare workers", "target_id": "COVID-19 vaccine", "strength": 7}, {"source_id": "SARS-CoV-2 infection", "target_id": "COVID-19", "strength": 3}, {"source_id": "COVID-19", "target_id": "SARS-CoV-2 infection", "strength": 3}, {"source_id": "herd immunity levels", "target_id": "herd immunity", "strength": 2}, {"source_id": "COVID-19 infection", "target_id": "seropositivity rate", "strength": 2}, {"source_id": "antibody response", "target_id": "cell epitopes", "strength": 2}, {"source_id": "cell epitopes", "target_id": "T cell responses", "strength": 2}, {"source_id": "T cells", "target_id": "SARS-CoV-2", "strength": 5}, {"source_id": "immune response", "target_id": "SARS-CoV-2", "strength": 11}, {"source_id": "BNT162b2 mRNA COVID-19 vaccine", "target_id": "immune response", "strength": 2}, {"source_id": "SARS-CoV-2 antibodies", "target_id": "SARS-CoV-2", "strength": 8}, {"source_id": "vaccine acceptance", "target_id": "vaccine hesitancy", "strength": 7}, {"source_id": "side effects", "target_id": "vaccine hesitancy", "strength": 3}, {"source_id": "side effects", "target_id": "vaccine acceptance", "strength": 2}, {"source_id": "United States", "target_id": "percent of GDP", "strength": 2}, {"source_id": "blood donors", "target_id": "SARS-CoV-2", "strength": 4}, {"source_id": "severe acute respiratory syndrome coronavirus 2", "target_id": "syndrome coronavirus 2", "strength": 3}, {"source_id": "severe acute respiratory syndrome coronavirus 2", "target_id": "coronavirus 2", "strength": 3}, {"source_id": "respiratory syndrome coronavirus 2", "target_id": "severe acute respiratory syndrome coronavirus 2", "strength": 3}, {"source_id": "herd immunity", "target_id": "immune response", "strength": 3}, {"source_id": "vaccine development", "target_id": "clinical trials", "strength": 2}, {"source_id": "COVID-19 vaccine", "target_id": "COVID-19 infection", "strength": 2}, {"source_id": "SARS-CoV-2 antibodies", "target_id": "SARS-CoV-2 infection", "strength": 8}, {"source_id": "COVID-19", "target_id": "SARS-CoV-2 antibodies", "strength": 4}, {"source_id": "side effects", "target_id": "vaccination program", "strength": 3}, {"source_id": "COVID-19 dynamics", "target_id": "random walk", "strength": 2}, {"source_id": "developed theory", "target_id": "ultrametric spaces", "strength": 2}, {"source_id": "developed theory", "target_id": "COVID-19 dynamics", "strength": 2}, {"source_id": "SIR model", "target_id": "COVID-19 dynamics", "strength": 2}, {"source_id": "SIR model", "target_id": "ultrametric model", "strength": 2}, {"source_id": "acute SARS-CoV-2 infection", "target_id": "B cells", "strength": 2}, {"source_id": "vaccination program", "target_id": "vaccine efficacy", "strength": 3}, {"source_id": "vaccine efficacy", "target_id": "non-pharmaceutical interventions", "strength": 2}, {"source_id": "IgG antibodies", "target_id": "seroprevalence study", "strength": 2}, {"source_id": "general population", "target_id": "vaccine effectiveness", "strength": 2}, {"source_id": "non-human primates", "target_id": "receptor-binding domain", "strength": 2}, {"source_id": "peptide vaccine", "target_id": "novel SARS-CoV-2 vaccines", "strength": 2}, {"source_id": "cell epitopes", "target_id": "T cell epitopes", "strength": 2}, {"source_id": "mass vaccination campaign", "target_id": "vaccine acceptance", "strength": 2}, {"source_id": "herd immunity benefits", "target_id": "vaccine characteristics", "strength": 2}, {"source_id": "vaccine characteristics", "target_id": "vaccine acceptance", "strength": 2}, {"source_id": "vaccine acceptance", "target_id": "vaccination campaign", "strength": 2}, {"source_id": "vaccination campaign", "target_id": "herd immunity", "strength": 3}, {"source_id": "vaccine refusal", "target_id": "mass vaccination campaign", "strength": 2}, {"source_id": "herd immunity", "target_id": "herd immunity benefits", "strength": 2}, {"source_id": "COVID-19 vaccine acceptance", "target_id": "COVID-19 vaccine", "strength": 4}, {"source_id": "incidence rate", "target_id": "COVID-19 cases", "strength": 2}, {"source_id": "SARS-CoV-2 IgG antibodies", "target_id": "SARS-CoV-2 antibodies", "strength": 2}, {"source_id": "SARS-CoV-2 IgG antibodies", "target_id": "SARS-CoV-2 IgG antibody test", "strength": 2}, {"source_id": "COVID-19 vaccine", "target_id": "general population", "strength": 5}, {"source_id": "immune response", "target_id": "antibody titres", "strength": 2}, {"source_id": "healthcare workers", "target_id": "vaccination campaign", "strength": 3}, {"source_id": "vaccination campaign", "target_id": "healthcare workers", "strength": 3}, {"source_id": "healthcare workers", "target_id": "COVID-19", "strength": 2}, {"source_id": "COVID-19", "target_id": "healthcare workers", "strength": 2}, {"source_id": "COVID-19 vaccination", "target_id": "public health experts", "strength": 2}, {"source_id": "SARS-CoV-2 antibodies", "target_id": "health care workers", "strength": 2}, {"source_id": "health care workers", "target_id": "seroprevalence estimates", "strength": 2}, {"source_id": "seroprevalence estimates", "target_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies", "strength": 2}, {"source_id": "cumulative incidence", "target_id": "seroprevalence estimates", "strength": 2}, {"source_id": "cumulative incidence", "target_id": "seroprevalence data", "strength": 2}, {"source_id": "seroprevalence data", "target_id": "seroprevalence estimates", "strength": 2}, {"source_id": "global burden", "target_id": "SARS-CoV-2 antibodies", "strength": 2}, {"source_id": "global burden", "target_id": "care workers", "strength": 2}, {"source_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies", "target_id": "care workers", "strength": 2}, {"source_id": "care workers", "target_id": "seroprevalence data", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "enzyme-linked immunosorbent assay", "strength": 3}, {"source_id": "SARS-CoV-2", "target_id": "healthy blood donors", "strength": 2}, {"source_id": "faster virus clearance", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "faster virus clearance", "target_id": "distinct symptomatology", "strength": 2}, {"source_id": "viral load", "target_id": "distinct symptomatology", "strength": 2}, {"source_id": "SARS-CoV-2 immune response", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "SARS-CoV-2 immune response", "target_id": "distinct symptomatology", "strength": 2}, {"source_id": "cancer patients", "target_id": "T cell responses", "strength": 2}, {"source_id": "vaccine hesitancy", "target_id": "healthcare workers", "strength": 2}, {"source_id": "vaccine hesitancy", "target_id": "vaccine acceptability", "strength": 2}, {"source_id": "long-term care facilities", "target_id": "risk groups", "strength": 2}, {"source_id": "number of infections", "target_id": "regular testing", "strength": 2}, {"source_id": "risk groups", "target_id": "regular testing", "strength": 2}, {"source_id": "immune response", "target_id": "humoral immune response", "strength": 4}, {"source_id": "vaccination hesitancy", "target_id": "healthcare workers", "strength": 2}, {"source_id": "COVID-19 vaccination", "target_id": "health workers", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "case series", "strength": 2}, {"source_id": "mild symptoms", "target_id": "systematic review", "strength": 2}, {"source_id": "infectious (Ct<30) subset", "target_id": "antigen test", "strength": 2}, {"source_id": "antigen test", "target_id": "Medical Center", "strength": 2}, {"source_id": "Medical Center", "target_id": "vaccine rollout", "strength": 2}, {"source_id": "post-exposure prophylaxis", "target_id": "mass vaccination", "strength": 2}, {"source_id": "herd immunity", "target_id": "post-exposure prophylaxis", "strength": 2}, {"source_id": "vaccination strategies", "target_id": "mass vaccination", "strength": 2}, {"source_id": "protective immunity", "target_id": "SARS-CoV-2", "strength": 3}, {"source_id": "herd immunity", "target_id": "vaccine strategies", "strength": 2}, {"source_id": "SARS-CoV-2-specific IgG", "target_id": "population immunity", "strength": 2}, {"source_id": "mathematical epidemiology", "target_id": "important mathematical models", "strength": 2}, {"source_id": "mathematical epidemiology", "target_id": "mathematical model", "strength": 2}, {"source_id": "vaccine uptake", "target_id": "young adults", "strength": 3}, {"source_id": "SARS-CoV-2 infection", "target_id": "first dose", "strength": 2}, {"source_id": "personal protective equipment", "target_id": "World Health Organization", "strength": 2}, {"source_id": "immune response", "target_id": "T cells", "strength": 3}, {"source_id": "enzyme-linked immunosorbent assay", "target_id": "blood donors", "strength": 2}, {"source_id": "New York City metropolitan area", "target_id": "high-throughput serological assays", "strength": 2}, {"source_id": "SARS-CoV-2 variants", "target_id": "herd immunity", "strength": 2}, {"source_id": "vaccination intention", "target_id": "vaccine hesitancy", "strength": 2}, {"source_id": "emergency department", "target_id": "COVID-19", "strength": 2}, {"source_id": "vaccine acceptance", "target_id": "cross-sectional study", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "long-term survival", "strength": 2}, {"source_id": "IgG index values", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "first dose", "target_id": "antibody titers", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "first dose", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "BNT162b2 vaccination", "strength": 2}, {"source_id": "antibody titers", "target_id": "first dose", "strength": 2}, {"source_id": "Delta variant", "target_id": "BNT162b2 vaccination", "strength": 2}, {"source_id": "positive externalities", "target_id": "non-cooperative solution", "strength": 2}, {"source_id": "social norms", "target_id": "non-cooperative solution", "strength": 2}, {"source_id": "herd immunity", "target_id": "COVID-19 infection", "strength": 4}, {"source_id": "COVID-19 vaccine", "target_id": "SARS-CoV-2 infection", "strength": 2}, {"source_id": "SARS-CoV-2-specific antibodies", "target_id": "humoral immune response", "strength": 2}, {"source_id": "care workers", "target_id": "SARS-CoV-2", "strength": 3}, {"source_id": "COVID-19 vaccination", "target_id": "COVID-19", "strength": 2}, {"source_id": "COVID-19", "target_id": "COVID-19 vaccination", "strength": 2}, {"source_id": "COVID-19 vaccination", "target_id": "vaccine uptake", "strength": 2}, {"source_id": "T cell responses", "target_id": "immune response", "strength": 2}, {"source_id": "COVID-19 diagnosis", "target_id": "positive household contacts", "strength": 2}, {"source_id": "logistic regression analysis", "target_id": "COVID-19 vaccination", "strength": 2}, {"source_id": "SARS-CoV-2 antibodies", "target_id": "retrospective closed cohort study", "strength": 2}, {"source_id": "COVID-19 vaccine hesitancy", "target_id": "herd immunity benefits", "strength": 2}, {"source_id": "mRNA vaccines", "target_id": "second dose", "strength": 2}, {"source_id": "severe disease", "target_id": "protective immunity", "strength": 2}, {"source_id": "herd immunity", "target_id": "viral infection", "strength": 2}, {"source_id": "economic activity", "target_id": "alternative policies", "strength": 2}, {"source_id": "economic activity", "target_id": "policy", "strength": 2}, {"source_id": "alternative policies", "target_id": "policy analysis", "strength": 2}, {"source_id": "policy", "target_id": "economic activity", "strength": 2}, {"source_id": "policy", "target_id": "numerical exercise", "strength": 2}, {"source_id": "Delta variant", "target_id": "vaccine effectiveness", "strength": 2}, {"source_id": "SARS-CoV-2-specific IgG antibodies", "target_id": "T cells", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "Delta variant", "strength": 6}, {"source_id": "side effects", "target_id": "herd immunity", "strength": 5}, {"source_id": "herd immunity", "target_id": "high-risk individuals", "strength": 3}, {"source_id": "vaccine acceptance", "target_id": "vaccine refusal", "strength": 3}, {"source_id": "immunity threshold", "target_id": "herd immunity", "strength": 7}, {"source_id": "vaccination rates", "target_id": "herd immunity threshold", "strength": 5}, {"source_id": "vaccination rates", "target_id": "herd immunity", "strength": 9}, {"source_id": "SARS-CoV-2 IgG antibodies", "target_id": "acute respiratory syndrome coronavirus 2 infection", "strength": 3}, {"source_id": "SARS-CoV-2 infection", "target_id": "past infection", "strength": 2}, {"source_id": "herd immunity threshold", "target_id": "infection fatality rate", "strength": 2}, {"source_id": "COVID-19 vaccine hesitancy", "target_id": "vaccine hesitancy", "strength": 22}, {"source_id": "underlying psychological processes", "target_id": "young people", "strength": 3}, {"source_id": "underlying psychological processes", "target_id": "personality trait scores", "strength": 3}, {"source_id": "underlying psychological processes", "target_id": "prosocial nature", "strength": 3}, {"source_id": "young people", "target_id": "underlying psychological processes", "strength": 3}, {"source_id": "young people", "target_id": "prosocial traits", "strength": 2}, {"source_id": "personality trait scores", "target_id": "underlying psychological processes", "strength": 3}, {"source_id": "personality trait scores", "target_id": "prosocial traits", "strength": 2}, {"source_id": "personality trait scores", "target_id": "COVID-19 vaccination", "strength": 3}, {"source_id": "different messages", "target_id": "prosocial nature", "strength": 2}, {"source_id": "herd immunity threshold", "target_id": "COVID-19", "strength": 4}, {"source_id": "optimization algorithm", "target_id": "coronavirus herd immunity optimizer", "strength": 3}, {"source_id": "search optimization", "target_id": "optimization algorithm", "strength": 2}, {"source_id": "COVID-19 vaccine", "target_id": "herd immunity", "strength": 17}, {"source_id": "severe disease", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "severe acute respiratory syndrome coronavirus type 2", "strength": 2}, {"source_id": "IgG antibodies", "target_id": "acute respiratory syndrome coronavirus 2 infection", "strength": 3}, {"source_id": "population immunity", "target_id": "herd immunity", "strength": 4}, {"source_id": "herd immunity", "target_id": "population immunity", "strength": 4}, {"source_id": "COVID-19 vaccine", "target_id": "healthcare professionals", "strength": 2}, {"source_id": "PCR positivity", "target_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic", "strength": 3}, {"source_id": "herd immunity", "target_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic", "strength": 2}, {"source_id": "herd immunity", "target_id": "vaccination intention", "strength": 2}, {"source_id": "vaccination intention", "target_id": "effective vaccine", "strength": 2}, {"source_id": "COVID-19", "target_id": "vaccination intention", "strength": 2}, {"source_id": "IgG antibodies", "target_id": "SARS-CoV-2 antibodies", "strength": 5}, {"source_id": "viral mutations", "target_id": "SARS-CoV-2 epidemic", "strength": 4}, {"source_id": "blood donors", "target_id": "herd immunity", "strength": 3}, {"source_id": "epidemic model", "target_id": "new dynamical equations", "strength": 2}, {"source_id": "epidemic model", "target_id": "network science", "strength": 2}, {"source_id": "SIR equations", "target_id": "new dynamical equations", "strength": 2}, {"source_id": "SIR model", "target_id": "network science", "strength": 2}, {"source_id": "SARS-CoV-2 infection", "target_id": "immune response", "strength": 5}, {"source_id": "immune response", "target_id": "SARS-CoV-2 infection", "strength": 5}, {"source_id": "SARS-CoV-2", "target_id": "antibody response", "strength": 5}, {"source_id": "COVID-19", "target_id": "SARS-CoV-2", "strength": 16}, {"source_id": "SARS-CoV-2 variants", "target_id": "mRNA vaccine recipients", "strength": 2}, {"source_id": "vaccine-induced immunity", "target_id": "population immunity", "strength": 2}, {"source_id": "SARS-CoV-2 variants", "target_id": "co-circulating SARS-CoV-2 variant", "strength": 2}, {"source_id": "vaccination coverage", "target_id": "vaccine hesitancy", "strength": 2}, {"source_id": "Delta variant", "target_id": "herd immunity", "strength": 4}, {"source_id": "COVID-19 vaccine", "target_id": "SARS-CoV-2 pandemic", "strength": 2}, {"source_id": "vaccine efficacy", "target_id": "mass vaccination", "strength": 3}, {"source_id": "vaccine hesitancy", "target_id": "COVID-19", "strength": 4}, {"source_id": "vaccine uptake", "target_id": "side effects", "strength": 2}, {"source_id": "side effects", "target_id": "COVID-19 vaccine", "strength": 11}, {"source_id": "side effects", "target_id": "online cross-sectional study", "strength": 2}, {"source_id": "unmet need", "target_id": "online cross-sectional study", "strength": 2}, {"source_id": "herd immunity", "target_id": "vaccine uptake", "strength": 5}, {"source_id": "COVID-19 infection", "target_id": "COVID-19 reinfection", "strength": 2}, {"source_id": "prior infection", "target_id": "COVID-19 reinfection", "strength": 2}, {"source_id": "asymptomatic cases", "target_id": "asymptomatic infection", "strength": 2}, {"source_id": "COVID-19 vaccine", "target_id": "Oxford-AstraZeneca COVID-19 vaccine", "strength": 2}, {"source_id": "COVID-19 cases", "target_id": "COVID-19", "strength": 3}, {"source_id": "COVID-19 vaccine", "target_id": "health professionals", "strength": 2}, {"source_id": "measles outbreak", "target_id": "population immunity", "strength": 2}, {"source_id": "population immunity", "target_id": "measles vaccination coverage", "strength": 2}, {"source_id": "welfare costs", "target_id": "poor countries", "strength": 2}, {"source_id": "welfare costs", "target_id": "agnostic view", "strength": 2}, {"source_id": "welfare costs", "target_id": "COVID-19 pandemic", "strength": 2}, {"source_id": "most countries", "target_id": "ratio of poverty", "strength": 2}, {"source_id": "most countries", "target_id": "welfare consequences", "strength": 2}, {"source_id": "most countries", "target_id": "agnostic view", "strength": 2}, {"source_id": "welfare losses", "target_id": "countries", "strength": 2}, {"source_id": "poverty effects", "target_id": "poor countries", "strength": 2}, {"source_id": "poverty effects", "target_id": "agnostic view", "strength": 2}, {"source_id": "poverty accounts", "target_id": "COVID-19 pandemic", "strength": 2}, {"source_id": "poverty accounts", "target_id": "countries", "strength": 2}, {"source_id": "agnostic view", "target_id": "most countries", "strength": 2}, {"source_id": "agnostic view", "target_id": "welfare consequences", "strength": 2}, {"source_id": "agnostic view", "target_id": "COVID-19 pandemic", "strength": 2}, {"source_id": "poverty", "target_id": "most countries", "strength": 2}, {"source_id": "poverty", "target_id": "welfare consequences", "strength": 2}, {"source_id": "poverty", "target_id": "greater share", "strength": 2}, {"source_id": "countries", "target_id": "most countries", "strength": 3}, {"source_id": "countries", "target_id": "poor countries", "strength": 2}, {"source_id": "countries", "target_id": "agnostic view", "strength": 2}, {"source_id": "countries", "target_id": "growth estimates", "strength": 2}, {"source_id": "growth estimates", "target_id": "poor countries", "strength": 2}, {"source_id": "growth estimates", "target_id": "countries", "strength": 2}, {"source_id": "variants of concern", "target_id": "SARS-CoV-2", "strength": 4}, {"source_id": "surrogate virus neutralization test", "target_id": "virus neutralization test", "strength": 2}, {"source_id": "infectious diseases", "target_id": "herd immunity", "strength": 8}, {"source_id": "herd immunity", "target_id": "infectious diseases", "strength": 8}, {"source_id": "immunized population", "target_id": "infectious diseases", "strength": 4}, {"source_id": "contact infection", "target_id": "infectious diseases", "strength": 6}, {"source_id": "contact infection", "target_id": "vaccination rates", "strength": 4}, {"source_id": "mathematical model", "target_id": "diffusion equation", "strength": 4}, {"source_id": "diffusion equation", "target_id": "standard mathematical model", "strength": 4}, {"source_id": "diffusion equation", "target_id": "ultrametric spaces", "strength": 4}, {"source_id": "diffusion equation", "target_id": "SIR model", "strength": 4}, {"source_id": "adic diffusion equation", "target_id": "adic number fields", "strength": 4}, {"source_id": "social hierarchy\u2019s levels", "target_id": "mathematical model", "strength": 6}, {"source_id": "social hierarchy\u2019s levels", "target_id": "adic number fields", "strength": 4}, {"source_id": "new mathematical model", "target_id": "standard mathematical model", "strength": 4}, {"source_id": "standard mathematical model", "target_id": "diffusion equation", "strength": 4}, {"source_id": "standard mathematical model", "target_id": "ultrametric spaces", "strength": 5}, {"source_id": "adic number fields", "target_id": "new mathematical model", "strength": 4}, {"source_id": "adic number fields", "target_id": "algebraic structure", "strength": 4}, {"source_id": "adic number fields", "target_id": "SIR model", "strength": 4}, {"source_id": "statistical physics", "target_id": "mathematical model", "strength": 5}, {"source_id": "statistical physics", "target_id": "adic diffusion equation", "strength": 4}, {"source_id": "statistical physics", "target_id": "new mathematical model", "strength": 4}, {"source_id": "algebraic structure", "target_id": "social hierarchy\u2019s levels", "strength": 4}, {"source_id": "ultrametric spaces", "target_id": "mathematical model", "strength": 7}, {"source_id": "ultrametric spaces", "target_id": "diffusion equation", "strength": 4}, {"source_id": "number field", "target_id": "mathematical model", "strength": 4}, {"source_id": "number field", "target_id": "statistical physics", "strength": 4}, {"source_id": "number field", "target_id": "SIR model", "strength": 4}, {"source_id": "SIR model", "target_id": "diffusion equation", "strength": 4}, {"source_id": "SIR model", "target_id": "standard mathematical model", "strength": 5}, {"source_id": "antibody-dependent enhancement", "target_id": "SARS-CoV-2", "strength": 4}, {"source_id": "herd immunity", "target_id": "antibody-dependent enhancement", "strength": 2}, {"source_id": "susceptible individuals", "target_id": "herd immunity threshold", "strength": 3}, {"source_id": "COVID-19 pandemic", "target_id": "public health policy", "strength": 2}, {"source_id": "COVID-19 pandemic", "target_id": "COVID-19", "strength": 2}, {"source_id": "mandatory vaccination policies", "target_id": "moral obligation", "strength": 2}, {"source_id": "justice", "target_id": "ethical values", "strength": 2}, {"source_id": "justice", "target_id": "ethical dilemmas", "strength": 2}, {"source_id": "ethics", "target_id": "moral obligation", "strength": 2}, {"source_id": "COVID-19 vaccine", "target_id": "Sputnik V", "strength": 2}, {"source_id": "COVID-19 vaccine", "target_id": "mRNA vaccines", "strength": 3}, {"source_id": "acute respiratory syndrome coronavirus 2 infection", "target_id": "COVID-19 vaccine", "strength": 4}, {"source_id": "B cells", "target_id": "memory B cells", "strength": 2}, {"source_id": "existence of hubs", "target_id": "ODE model", "strength": 2}, {"source_id": "dynamical evolution", "target_id": "stochastic simulation", "strength": 2}, {"source_id": "mathematical modeling", "target_id": "ODE model", "strength": 2}, {"source_id": "mathematical modeling", "target_id": "dynamical evolution", "strength": 3}, {"source_id": "mathematical modeling", "target_id": "point estimates", "strength": 2}, {"source_id": "emergency use authorization", "target_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection", "strength": 2}, {"source_id": "adverse events", "target_id": "COVID-19 vaccine", "strength": 4}, {"source_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection", "target_id": "emergency use authorization", "strength": 2}, {"source_id": "COVID-19 vaccination program", "target_id": "vaccination program", "strength": 4}, {"source_id": "COVID-19 vaccination", "target_id": "vaccination program", "strength": 5}, {"source_id": "health care workers", "target_id": "SARS-CoV-2", "strength": 6}, {"source_id": "SARS-CoV-2", "target_id": "asymptomatic SARS-CoV-2 infection", "strength": 2}, {"source_id": "asymptomatic SARS-CoV-2 infection", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "SARS-CoV-2 T-cell response", "target_id": "T cell responses", "strength": 2}, {"source_id": "SARS-CoV-2 T-cell response", "target_id": "cell epitopes", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "immune response", "strength": 11}, {"source_id": "SARS-CoV-2", "target_id": "BNT162b2 mRNA COVID-19 vaccine", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "SARS-CoV-2 antibodies", "strength": 8}, {"source_id": "adverse events", "target_id": "SARS-CoV-2", "strength": 3}, {"source_id": "COVID-19 vaccine hesitancy", "target_id": "vaccine acceptance", "strength": 3}, {"source_id": "vaccine hesitancy", "target_id": "vaccine acceptance", "strength": 7}, {"source_id": "vaccine hesitancy", "target_id": "side effects", "strength": 3}, {"source_id": "vaccine acceptance", "target_id": "COVID-19 vaccine hesitancy", "strength": 3}, {"source_id": "COVID-19 patients", "target_id": "SARS-CoV-2", "strength": 3}, {"source_id": "SARS-CoV-2", "target_id": "blood donors", "strength": 4}, {"source_id": "blood donors", "target_id": "IgG antibodies", "strength": 4}, {"source_id": "IgG antibodies", "target_id": "SARS-CoV-2", "strength": 6}, {"source_id": "power-law dynamics", "target_id": "critical behavior", "strength": 2}, {"source_id": "coronavirus 2", "target_id": "respiratory syndrome coronavirus 2", "strength": 3}, {"source_id": "SARS-CoV-2", "target_id": "severe acute respiratory syndrome", "strength": 2}, {"source_id": "severe acute respiratory syndrome", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "vaccine development", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "clinical trials", "target_id": "immune response", "strength": 2}, {"source_id": "symptom onset", "target_id": "COVID-19 patients", "strength": 2}, {"source_id": "SARS-CoV-2 infection", "target_id": "SARS-CoV-2 antibodies", "strength": 8}, {"source_id": "vaccination program", "target_id": "general population", "strength": 2}, {"source_id": "side effects", "target_id": "COVID-19 vaccination", "strength": 5}, {"source_id": "developed theory", "target_id": "social hierarchy\u2019s levels", "strength": 2}, {"source_id": "ultrametric model", "target_id": "social hierarchy\u2019s levels", "strength": 2}, {"source_id": "ultrametric model", "target_id": "SIR model", "strength": 2}, {"source_id": "herd immunity", "target_id": "vaccine efficacy", "strength": 6}, {"source_id": "vaccine efficacy", "target_id": "herd immunity", "strength": 6}, {"source_id": "vaccine efficacy", "target_id": "immunity duration", "strength": 2}, {"source_id": "mass vaccination", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "COVID-19 cases", "target_id": "herd immunity", "strength": 6}, {"source_id": "non-human primates", "target_id": "peptide vaccine", "strength": 2}, {"source_id": "vaccine candidates", "target_id": "SARS-CoV-2", "strength": 3}, {"source_id": "humoral response", "target_id": "SARS-CoV-2", "strength": 3}, {"source_id": "vaccination hesitancy", "target_id": "vaccine hesitancy", "strength": 3}, {"source_id": "SARS-CoV-2", "target_id": "COVID-19 infection", "strength": 2}, {"source_id": "COVID-19 infection", "target_id": "COVID-19", "strength": 4}, {"source_id": "herd immunity benefits", "target_id": "vaccine refusal", "strength": 2}, {"source_id": "herd immunity benefits", "target_id": "herd immunity", "strength": 2}, {"source_id": "vaccination campaign", "target_id": "herd immunity benefits", "strength": 2}, {"source_id": "vaccination campaign", "target_id": "vaccine characteristics", "strength": 2}, {"source_id": "non-pharmaceutical interventions", "target_id": "SARS-CoV-2", "strength": 4}, {"source_id": "COVID-19 vaccine", "target_id": "COVID-19 vaccine acceptance", "strength": 4}, {"source_id": "COVID-19 vaccine", "target_id": "vaccine safety", "strength": 3}, {"source_id": "vaccine safety", "target_id": "COVID-19 vaccine", "strength": 3}, {"source_id": "booster dose", "target_id": "second dose", "strength": 2}, {"source_id": "antibody titres", "target_id": "immune response", "strength": 2}, {"source_id": "COVID-19 vaccine intention", "target_id": "vaccine intentions", "strength": 4}, {"source_id": "non-pharmaceutical interventions", "target_id": "herd immunity", "strength": 2}, {"source_id": "SARS-CoV-2 antibodies", "target_id": "cumulative incidence", "strength": 2}, {"source_id": "SARS-CoV-2 antibodies", "target_id": "systematic review", "strength": 2}, {"source_id": "SARS-CoV-2 infection", "target_id": "seroprevalence data", "strength": 2}, {"source_id": "SARS-CoV-2 infection", "target_id": "care workers", "strength": 2}, {"source_id": "SARS-CoV-2 infection", "target_id": "systematic review", "strength": 2}, {"source_id": "health care workers", "target_id": "seroprevalence data", "strength": 2}, {"source_id": "health care workers", "target_id": "care workers", "strength": 8}, {"source_id": "seroprevalence estimates", "target_id": "seroprevalence data", "strength": 2}, {"source_id": "seroprevalence data", "target_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies", "strength": 2}, {"source_id": "global burden", "target_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies", "strength": 2}, {"source_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies", "target_id": "health care workers", "strength": 2}, {"source_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies", "target_id": "seroprevalence data", "strength": 2}, {"source_id": "care workers", "target_id": "seroprevalence estimates", "strength": 2}, {"source_id": "viral load", "target_id": "SARS-CoV-2 immune response", "strength": 2}, {"source_id": "T cell responses", "target_id": "cancer patients", "strength": 2}, {"source_id": "cancer patients", "target_id": "COVID-19 vaccine", "strength": 2}, {"source_id": "SARS-CoV-2 seroprevalence", "target_id": "COVID-19 cases", "strength": 2}, {"source_id": "healthcare workers", "target_id": "COVID-19 vaccination", "strength": 2}, {"source_id": "long-term care facilities", "target_id": "regular testing", "strength": 2}, {"source_id": "number of infections", "target_id": "long-term care facilities", "strength": 2}, {"source_id": "risk groups", "target_id": "long-term care facilities", "strength": 2}, {"source_id": "care facilities", "target_id": "long-term care facilities", "strength": 4}, {"source_id": "care facilities", "target_id": "number of infections", "strength": 2}, {"source_id": "care facilities", "target_id": "risk groups", "strength": 2}, {"source_id": "herd immunity", "target_id": "enzyme-linked immunosorbent assay", "strength": 2}, {"source_id": "vaccination acceptance", "target_id": "vaccination hesitancy", "strength": 2}, {"source_id": "vaccine hesitancy", "target_id": "vaccine uptake", "strength": 4}, {"source_id": "infectious (Ct<30) subset", "target_id": "Medical Center", "strength": 2}, {"source_id": "Medical Center", "target_id": "antigen test", "strength": 2}, {"source_id": "high antibody titers", "target_id": "antibody titers", "strength": 2}, {"source_id": "vaccination strategies", "target_id": "post-exposure prophylaxis", "strength": 2}, {"source_id": "herd immunity", "target_id": "vaccine policy", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "SARS-CoV-2 vaccines", "strength": 4}, {"source_id": "SARS-CoV-2 infection", "target_id": "SARS-CoV-2 vaccines", "strength": 3}, {"source_id": "vaccine strategies", "target_id": "herd immunity", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "personal protective equipment", "strength": 2}, {"source_id": "personal protective equipment", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "vaccine hesitancy", "target_id": "mandatory vaccination", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "population immunity", "strength": 5}, {"source_id": "electricity market data", "target_id": "robustness tests", "strength": 2}, {"source_id": "macroeconomic indicators", "target_id": "robustness tests", "strength": 2}, {"source_id": "domestic product", "target_id": "GDP loss", "strength": 2}, {"source_id": "domestic product", "target_id": "robustness tests", "strength": 2}, {"source_id": "antibody response", "target_id": "SARS-CoV-2 infection", "strength": 2}, {"source_id": "side effects", "target_id": "vaccination intention", "strength": 2}, {"source_id": "vaccine uptake", "target_id": "vaccination intention", "strength": 2}, {"source_id": "World Health Organization", "target_id": "personal protective equipment", "strength": 2}, {"source_id": "T cells", "target_id": "immune response", "strength": 3}, {"source_id": "enzyme-linked immunosorbent assay", "target_id": "high-throughput serological assays", "strength": 2}, {"source_id": "New York City metropolitan area", "target_id": "enzyme-linked immunosorbent assay", "strength": 2}, {"source_id": "COVID-19 vaccine intention", "target_id": "herd immunity", "strength": 3}, {"source_id": "herd immunity", "target_id": "vaccine intentions", "strength": 3}, {"source_id": "asymptomatic SARS-CoV-2 infection", "target_id": "SARS-CoV-2 infection", "strength": 2}, {"source_id": "neutralization test", "target_id": "receptor-binding domain", "strength": 2}, {"source_id": "receptor-binding domain", "target_id": "neutralization test", "strength": 2}, {"source_id": "herd immunity", "target_id": "immune individuals", "strength": 2}, {"source_id": "antibody titers", "target_id": "BNT162b2 vaccination", "strength": 2}, {"source_id": "Delta variant", "target_id": "first dose", "strength": 2}, {"source_id": "low prevalence", "target_id": "vaccine hesitancy", "strength": 2}, {"source_id": "low prevalence", "target_id": "cross-sectional survey", "strength": 2}, {"source_id": "free-rider problem", "target_id": "non-cooperative solution", "strength": 2}, {"source_id": "free-rider problem", "target_id": "social norms", "strength": 2}, {"source_id": "positive externalities", "target_id": "Nash equilibrium", "strength": 2}, {"source_id": "social norms", "target_id": "positive externalities", "strength": 2}, {"source_id": "social norms", "target_id": "game-theoretic analysis", "strength": 2}, {"source_id": "game-theoretic approach", "target_id": "positive externalities", "strength": 2}, {"source_id": "COVID-19", "target_id": "vaccine efficacy", "strength": 2}, {"source_id": "SIR model", "target_id": "stochastic SIR model", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic", "strength": 2}, {"source_id": "immune response", "target_id": "SARS-CoV-2-specific antibodies", "strength": 2}, {"source_id": "SARS-CoV-2-specific antibodies", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "SARS-CoV-2 subunit vaccine", "strength": 2}, {"source_id": "NAb titers", "target_id": "antibody titers", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "care workers", "strength": 3}, {"source_id": "immune response", "target_id": "T cell responses", "strength": 2}, {"source_id": "implementation of NPIs", "target_id": "non-pharmaceutical interventions", "strength": 2}, {"source_id": "COVID-19", "target_id": "side effects", "strength": 2}, {"source_id": "immune response", "target_id": "SARS-CoV-2 vaccines", "strength": 2}, {"source_id": "COVID-19", "target_id": "more symptoms", "strength": 2}, {"source_id": "COVID-19", "target_id": "COVID-19 diagnosis", "strength": 2}, {"source_id": "mathematical model", "target_id": "random walk", "strength": 3}, {"source_id": "antiviral drugs", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "mRNA vaccines", "target_id": "first dose", "strength": 2}, {"source_id": "acute respiratory syndrome coronavirus 2 infection", "target_id": "SARS-CoV-2 infection", "strength": 2}, {"source_id": "COVID-19", "target_id": "COVID-19 patients", "strength": 2}, {"source_id": "protective immunity", "target_id": "severe disease", "strength": 2}, {"source_id": "vaccine hesitancy", "target_id": "vaccination strategies", "strength": 2}, {"source_id": "vaccination campaign", "target_id": "COVID-19 vaccination", "strength": 3}, {"source_id": "policy analysis", "target_id": "alternative policies", "strength": 2}, {"source_id": "alternative policies", "target_id": "numerical exercise", "strength": 2}, {"source_id": "T cells", "target_id": "SARS-CoV-2-specific IgG antibodies", "strength": 2}, {"source_id": "vaccinated individuals", "target_id": "herd immunity", "strength": 2}, {"source_id": "mass vaccination", "target_id": "herd immunity", "strength": 9}, {"source_id": "Omicron variant", "target_id": "SARS-CoV-2", "strength": 3}, {"source_id": "high-risk individuals", "target_id": "herd immunity", "strength": 3}, {"source_id": "herd immunity", "target_id": "vaccination program", "strength": 9}, {"source_id": "SARS-CoV-2", "target_id": "herd immunity", "strength": 42}, {"source_id": "SARS-CoV-2", "target_id": "SARS-CoV-2 IgG antibodies", "strength": 6}, {"source_id": "acute respiratory syndrome coronavirus 2 infection", "target_id": "SARS-CoV-2", "strength": 5}, {"source_id": "infection fatality rate", "target_id": "herd immunity threshold", "strength": 2}, {"source_id": "herd immunity threshold", "target_id": "SARS-CoV-2", "strength": 5}, {"source_id": "vaccine hesitancy", "target_id": "adverse reactions", "strength": 2}, {"source_id": "vaccine hesitancy", "target_id": "vaccination campaign", "strength": 3}, {"source_id": "adverse reactions", "target_id": "COVID-19 vaccine hesitancy", "strength": 2}, {"source_id": "vaccination campaign", "target_id": "vaccine hesitancy", "strength": 3}, {"source_id": "underlying psychological processes", "target_id": "prosocial traits", "strength": 2}, {"source_id": "young people", "target_id": "prosocial nature", "strength": 3}, {"source_id": "young people", "target_id": "COVID-19 vaccination", "strength": 3}, {"source_id": "personality trait scores", "target_id": "young people", "strength": 3}, {"source_id": "different messages", "target_id": "prosocial traits", "strength": 2}, {"source_id": "COVID-19", "target_id": "immunity threshold", "strength": 4}, {"source_id": "coronavirus herd immunity optimizer", "target_id": "neural network", "strength": 2}, {"source_id": "coronavirus herd immunity optimizer", "target_id": "search space", "strength": 2}, {"source_id": "coronavirus herd immunity optimizer", "target_id": "classification accuracy", "strength": 2}, {"source_id": "benchmark datasets", "target_id": "search space", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "SARS-CoV-2 vaccination", "strength": 2}, {"source_id": "booster vaccination", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "booster vaccination", "target_id": "severe acute respiratory syndrome coronavirus type 2", "strength": 2}, {"source_id": "severe acute respiratory syndrome coronavirus type 2", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "SARS-CoV-2 IgG antibodies", "target_id": "IgG antibodies", "strength": 9}, {"source_id": "COVID-19 vaccination", "target_id": "COVID-19 vaccine", "strength": 11}, {"source_id": "herd immunity", "target_id": "SARS-CoV-2 infection", "strength": 8}, {"source_id": "IgG antibodies", "target_id": "COVID-19 infection", "strength": 2}, {"source_id": "effective vaccine", "target_id": "herd immunity", "strength": 3}, {"source_id": "healthy blood donors", "target_id": "blood donors", "strength": 6}, {"source_id": "healthcare workers", "target_id": "blood donors", "strength": 2}, {"source_id": "SARS-CoV-2 antibodies", "target_id": "blood donors", "strength": 4}, {"source_id": "healthy blood donors", "target_id": "seroprevalence rates", "strength": 3}, {"source_id": "seroprevalence rates", "target_id": "SARS-CoV-2 antibodies", "strength": 3}, {"source_id": "blood donors", "target_id": "SARS-CoV-2 antibodies", "strength": 4}, {"source_id": "herd immunity", "target_id": "SARS-CoV-2 antibodies", "strength": 5}, {"source_id": "SIR model", "target_id": "new dynamical equations", "strength": 2}, {"source_id": "network science", "target_id": "epidemic model", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "SARS-CoV-2 variants", "strength": 6}, {"source_id": "SARS-CoV-2 variants", "target_id": "SARS-CoV-2", "strength": 6}, {"source_id": "SARS-CoV-2", "target_id": "COVID-19", "strength": 16}, {"source_id": "new SARS-CoV-2 variants", "target_id": "SARS-CoV-2 variants", "strength": 2}, {"source_id": "new SARS-CoV-2 variants", "target_id": "co-circulating SARS-CoV-2 variant", "strength": 2}, {"source_id": "US population", "target_id": "SARS-CoV-2 variants", "strength": 2}, {"source_id": "US population", "target_id": "co-circulating SARS-CoV-2 variant", "strength": 2}, {"source_id": "vaccine hesitancy", "target_id": "vaccination coverage", "strength": 2}, {"source_id": "COVID-19 cases", "target_id": "COVID-19 infection", "strength": 3}, {"source_id": "vaccination coverage", "target_id": "herd immunity", "strength": 5}, {"source_id": "mortality rate", "target_id": "number of deaths", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "viral infection", "strength": 3}, {"source_id": "COVID-19", "target_id": "vaccine hesitancy", "strength": 4}, {"source_id": "cross-sectional study", "target_id": "side effects", "strength": 3}, {"source_id": "vaccine uptake", "target_id": "COVID-19 vaccine", "strength": 7}, {"source_id": "vaccine uptake", "target_id": "online cross-sectional study", "strength": 2}, {"source_id": "prior infection", "target_id": "COVID-19 infection", "strength": 2}, {"source_id": "individuals' willingness", "target_id": "willingness", "strength": 2}, {"source_id": "vaccine acceptance", "target_id": "herd immunity", "strength": 4}, {"source_id": "COVID-19 vaccine", "target_id": "vaccine acceptance", "strength": 8}, {"source_id": "measles outbreak", "target_id": "measles vaccination coverage", "strength": 2}, {"source_id": "measles outbreak", "target_id": "vaccination coverage", "strength": 2}, {"source_id": "welfare losses", "target_id": "ratio of poverty", "strength": 2}, {"source_id": "welfare losses", "target_id": "agnostic view", "strength": 2}, {"source_id": "poverty effects", "target_id": "greater share", "strength": 2}, {"source_id": "poverty accounts", "target_id": "welfare consequences", "strength": 2}, {"source_id": "poverty accounts", "target_id": "greater share", "strength": 2}, {"source_id": "poverty accounts", "target_id": "growth estimates", "strength": 2}, {"source_id": "agnostic view", "target_id": "ratio of poverty", "strength": 2}, {"source_id": "poverty", "target_id": "ratio of poverty", "strength": 2}, {"source_id": "poverty", "target_id": "countries", "strength": 2}, {"source_id": "poverty", "target_id": "growth estimates", "strength": 2}, {"source_id": "COVID-19 pandemic", "target_id": "greater share", "strength": 2}, {"source_id": "COVID-19 pandemic", "target_id": "countries", "strength": 4}, {"source_id": "countries", "target_id": "ratio of poverty", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "variants of concern", "strength": 4}, {"source_id": "antibody levels", "target_id": "herd immunity", "strength": 2}, {"source_id": "herd immunity", "target_id": "antibody levels", "strength": 2}, {"source_id": "herd immunity", "target_id": "IgG antibodies", "strength": 3}, {"source_id": "neutralization test", "target_id": "SARS-CoV-2 surrogate virus neutralization test", "strength": 2}, {"source_id": "neutralization test", "target_id": "virus neutralization test", "strength": 2}, {"source_id": "vaccination rates", "target_id": "infectious diseases", "strength": 4}, {"source_id": "immunized population", "target_id": "vaccination rates", "strength": 4}, {"source_id": "mathematical model", "target_id": "adic number fields", "strength": 4}, {"source_id": "mathematical model", "target_id": "number field", "strength": 4}, {"source_id": "diffusion equation", "target_id": "algebraic structure", "strength": 4}, {"source_id": "adic diffusion equation", "target_id": "algebraic structure", "strength": 4}, {"source_id": "adic diffusion equation", "target_id": "number field", "strength": 4}, {"source_id": "adic diffusion equation", "target_id": "SIR model", "strength": 4}, {"source_id": "social hierarchy\u2019s levels", "target_id": "standard mathematical model", "strength": 5}, {"source_id": "new mathematical model", "target_id": "adic diffusion equation", "strength": 4}, {"source_id": "new mathematical model", "target_id": "algebraic structure", "strength": 4}, {"source_id": "new mathematical model", "target_id": "ultrametric spaces", "strength": 4}, {"source_id": "standard mathematical model", "target_id": "mathematical model", "strength": 5}, {"source_id": "adic number fields", "target_id": "mathematical model", "strength": 4}, {"source_id": "adic number fields", "target_id": "number field", "strength": 4}, {"source_id": "statistical physics", "target_id": "diffusion equation", "strength": 4}, {"source_id": "statistical physics", "target_id": "number field", "strength": 4}, {"source_id": "algebraic structure", "target_id": "diffusion equation", "strength": 4}, {"source_id": "algebraic structure", "target_id": "adic diffusion equation", "strength": 4}, {"source_id": "algebraic structure", "target_id": "SIR model", "strength": 4}, {"source_id": "ultrametric spaces", "target_id": "SIR model", "strength": 6}, {"source_id": "number field", "target_id": "diffusion equation", "strength": 4}, {"source_id": "number field", "target_id": "adic diffusion equation", "strength": 4}, {"source_id": "number field", "target_id": "standard mathematical model", "strength": 4}, {"source_id": "number field", "target_id": "adic number fields", "strength": 4}, {"source_id": "SIR model", "target_id": "mathematical model", "strength": 7}, {"source_id": "SIR model", "target_id": "adic diffusion equation", "strength": 4}, {"source_id": "herd immunity threshold", "target_id": "susceptible individuals", "strength": 3}, {"source_id": "susceptible individuals", "target_id": "herd immunity", "strength": 8}, {"source_id": "number of infections", "target_id": "risk groups", "strength": 3}, {"source_id": "risk groups", "target_id": "number of infections", "strength": 3}, {"source_id": "public trust", "target_id": "COVID-19", "strength": 2}, {"source_id": "policy", "target_id": "COVID-19 pandemic", "strength": 2}, {"source_id": "COVID-19", "target_id": "COVID-19 pandemic", "strength": 2}, {"source_id": "mRNA vaccines", "target_id": "Sputnik V", "strength": 2}, {"source_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection", "target_id": "COVID-19 vaccine", "strength": 4}, {"source_id": "acute respiratory syndrome coronavirus 2 infection", "target_id": "mRNA vaccines", "strength": 2}, {"source_id": "immune memory", "target_id": "immune response", "strength": 2}, {"source_id": "existence of hubs", "target_id": "mathematical modeling", "strength": 2}, {"source_id": "existence of hubs", "target_id": "epidemic dynamics", "strength": 2}, {"source_id": "dynamical evolution", "target_id": "epidemic dynamics", "strength": 2}, {"source_id": "epidemic dynamics", "target_id": "mathematical modeling", "strength": 2}, {"source_id": "epidemic dynamics", "target_id": "point estimates", "strength": 2}, {"source_id": "epidemic dynamics", "target_id": "stochastic simulation", "strength": 2}, {"source_id": "COVID-19 vaccine", "target_id": "adverse events", "strength": 4}, {"source_id": "vaccination program", "target_id": "COVID-19 vaccination", "strength": 5}, {"source_id": "COVID-19 vaccine", "target_id": "healthcare workers", "strength": 7}, {"source_id": "receptor-binding domain", "target_id": "SARS-CoV-2", "strength": 4}, {"source_id": "T cell responses", "target_id": "antibody response", "strength": 2}, {"source_id": "antibody response", "target_id": "T cell responses", "strength": 2}, {"source_id": "cell epitopes", "target_id": "antibody response", "strength": 2}, {"source_id": "immune response", "target_id": "second dose", "strength": 4}, {"source_id": "immune response", "target_id": "BNT162b2 mRNA COVID-19 vaccine", "strength": 2}, {"source_id": "second dose", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "BNT162b2 mRNA COVID-19 vaccine", "target_id": "SARS-CoV-2 infection", "strength": 2}, {"source_id": "herd immunity", "target_id": "SARS-CoV-2 transmission", "strength": 2}, {"source_id": "vaccine acceptance", "target_id": "side effects", "strength": 2}, {"source_id": "IgG antibodies", "target_id": "blood donors", "strength": 4}, {"source_id": "topological dimension", "target_id": "regular graphs", "strength": 2}, {"source_id": "susceptible individuals", "target_id": "infectious diseases", "strength": 2}, {"source_id": "acute respiratory syndrome coronavirus 2", "target_id": "respiratory syndrome coronavirus 2", "strength": 3}, {"source_id": "syndrome coronavirus 2", "target_id": "severe acute respiratory syndrome coronavirus 2", "strength": 3}, {"source_id": "immune response", "target_id": "clinical trials", "strength": 2}, {"source_id": "herd immunity", "target_id": "vaccine development", "strength": 4}, {"source_id": "vaccine development", "target_id": "herd immunity", "strength": 4}, {"source_id": "COVID-19 vaccine", "target_id": "vaccine effectiveness", "strength": 5}, {"source_id": "vaccination intention", "target_id": "COVID-19 vaccine", "strength": 6}, {"source_id": "herd immunity", "target_id": "incremental cost-effectiveness ratio", "strength": 2}, {"source_id": "COVID-19 infection", "target_id": "COVID-19 vaccine", "strength": 2}, {"source_id": "prior infection", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "prior infection", "strength": 2}, {"source_id": "COVID-19 vaccination", "target_id": "side effects", "strength": 5}, {"source_id": "random walk", "target_id": "SIR model", "strength": 2}, {"source_id": "COVID-19 dynamics", "target_id": "ultrametric spaces", "strength": 2}, {"source_id": "developed theory", "target_id": "random walk", "strength": 2}, {"source_id": "ultrametric model", "target_id": "ultrametric spaces", "strength": 3}, {"source_id": "SARS-CoV", "target_id": "SARS-CoV-2", "strength": 3}, {"source_id": "vaccination rates", "target_id": "vaccine efficacy", "strength": 2}, {"source_id": "immunity duration", "target_id": "vaccine efficacy", "strength": 2}, {"source_id": "herd immunity", "target_id": "global herd immunity", "strength": 3}, {"source_id": "seroprevalence study", "target_id": "recent SARS-CoV-2 infection", "strength": 2}, {"source_id": "health care workers", "target_id": "systematic review", "strength": 3}, {"source_id": "vaccine effectiveness", "target_id": "SARS-CoV-2 infection", "strength": 3}, {"source_id": "unvaccinated participants", "target_id": "general population", "strength": 2}, {"source_id": "receptor-binding domain", "target_id": "novel SARS-CoV-2 vaccines", "strength": 2}, {"source_id": "peptide vaccine", "target_id": "non-human primates", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "vaccine candidates", "strength": 3}, {"source_id": "herd immunity", "target_id": "healthcare workers", "strength": 3}, {"source_id": "SARS-CoV-2", "target_id": "cellular immune responses", "strength": 2}, {"source_id": "cross-sectional study", "target_id": "COVID-19 infection", "strength": 2}, {"source_id": "COVID-19", "target_id": "COVID-19 infection", "strength": 4}, {"source_id": "mass vaccination campaign", "target_id": "vaccine characteristics", "strength": 2}, {"source_id": "mass vaccination campaign", "target_id": "herd immunity", "strength": 2}, {"source_id": "herd immunity benefits", "target_id": "mass vaccination campaign", "strength": 2}, {"source_id": "vaccine hesitancy", "target_id": "vaccine refusal", "strength": 2}, {"source_id": "vaccine acceptance", "target_id": "herd immunity benefits", "strength": 3}, {"source_id": "vaccine acceptance", "target_id": "vaccine characteristics", "strength": 2}, {"source_id": "vaccine refusal", "target_id": "herd immunity benefits", "strength": 2}, {"source_id": "herd immunity", "target_id": "vaccine refusal", "strength": 2}, {"source_id": "SARS-CoV-2 antibodies", "target_id": "SARS-CoV-2 IgG antibodies", "strength": 2}, {"source_id": "cross-sectional study", "target_id": "vaccine hesitancy", "strength": 2}, {"source_id": "general population", "target_id": "COVID-19 vaccine", "strength": 5}, {"source_id": "SARS-CoV-2 antibodies", "target_id": "care workers", "strength": 2}, {"source_id": "SARS-CoV-2 infection", "target_id": "health care workers", "strength": 3}, {"source_id": "seroprevalence estimates", "target_id": "SARS-CoV-2 antibodies", "strength": 2}, {"source_id": "seroprevalence estimates", "target_id": "SARS-CoV-2 infection", "strength": 2}, {"source_id": "seroprevalence estimates", "target_id": "systematic review", "strength": 2}, {"source_id": "cumulative incidence", "target_id": "health care workers", "strength": 2}, {"source_id": "cumulative incidence", "target_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies", "strength": 2}, {"source_id": "cumulative incidence", "target_id": "care workers", "strength": 2}, {"source_id": "cumulative incidence", "target_id": "systematic review", "strength": 2}, {"source_id": "seroprevalence data", "target_id": "health care workers", "strength": 2}, {"source_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies", "target_id": "SARS-CoV-2 antibodies", "strength": 2}, {"source_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies", "target_id": "cumulative incidence", "strength": 2}, {"source_id": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies", "target_id": "systematic review", "strength": 2}, {"source_id": "care workers", "target_id": "health care workers", "strength": 8}, {"source_id": "systematic review", "target_id": "cumulative incidence", "strength": 2}, {"source_id": "vaccination campaign", "target_id": "vaccination program", "strength": 3}, {"source_id": "COVID-19 vaccine", "target_id": "cancer patients", "strength": 2}, {"source_id": "COVID-19 cases", "target_id": "SARS-CoV-2 seroprevalence", "strength": 2}, {"source_id": "years of age", "target_id": "COVID-19", "strength": 2}, {"source_id": "Omicron variant", "target_id": "herd immunity", "strength": 2}, {"source_id": "humoral immune response", "target_id": "immune response", "strength": 4}, {"source_id": "vaccination hesitancy", "target_id": "vaccination acceptance", "strength": 2}, {"source_id": "healthcare workers", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "serological tests", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "vaccination program", "target_id": "immunization levels", "strength": 2}, {"source_id": "health workers", "target_id": "COVID-19 vaccination", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "mild symptoms", "strength": 2}, {"source_id": "systematic review", "target_id": "mild symptoms", "strength": 2}, {"source_id": "asymptomatic presentation", "target_id": "Medical Center", "strength": 2}, {"source_id": "mass vaccination", "target_id": "post-exposure prophylaxis", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "protective immunity", "strength": 3}, {"source_id": "SARS-CoV-2", "target_id": "cellular immunity", "strength": 2}, {"source_id": "cellular immunity", "target_id": "SARS-CoV-2 infection", "strength": 2}, {"source_id": "mathematical model", "target_id": "important mathematical models", "strength": 2}, {"source_id": "GDP loss", "target_id": "robustness tests", "strength": 2}, {"source_id": "young adults", "target_id": "vaccine uptake", "strength": 3}, {"source_id": "first dose", "target_id": "SARS-CoV-2 infection", "strength": 2}, {"source_id": "herd immunity", "target_id": "COVID-19 vaccine intention", "strength": 3}, {"source_id": "herd immunity", "target_id": "SARS-CoV-2 variants", "strength": 2}, {"source_id": "SARS-CoV-2", "target_id": "respiratory tract", "strength": 2}, {"source_id": "vaccination program", "target_id": "COVID-19", "strength": 3}, {"source_id": "vaccine hesitancy", "target_id": "COVID-19 vaccination intention", "strength": 2}, {"source_id": "vaccine hesitancy", "target_id": "vaccination intention", "strength": 2}, {"source_id": "first dose", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "first dose", "target_id": "Delta variant", "strength": 2}, {"source_id": "BNT162b2 vaccination", "target_id": "first dose", "strength": 2}, {"source_id": "COVID-19 vaccine", "target_id": "cross-sectional survey", "strength": 2}, {"source_id": "low prevalence", "target_id": "COVID-19 vaccine", "strength": 2}, {"source_id": "free-rider problem", "target_id": "positive externalities", "strength": 2}, {"source_id": "positive externalities", "target_id": "social norms", "strength": 2}, {"source_id": "COVID-19 infection", "target_id": "herd immunity", "strength": 4}, {"source_id": "SARS-CoV-2", "target_id": "SARS-CoV-2-specific antibodies", "strength": 2}, {"source_id": "realistic numerical example", "target_id": "mathematical analysis", "strength": 2}, {"source_id": "antibody titers", "target_id": "NAb titers", "strength": 2}, {"source_id": "feature selection", "target_id": "coronavirus herd immunity optimizer", "strength": 2}, {"source_id": "cancer patients", "target_id": "SARS-CoV-2", "strength": 2}, {"source_id": "COVID-19 vaccination", "target_id": "COVID-19 vaccine hesitancy", "strength": 2}, {"source_id": "COVID-19 diagnosis", "target_id": "household contacts", "strength": 2}, {"source_id": "COVID-19", "target_id": "presence of anosmia", "strength": 2}, {"source_id": "COVID-19", "target_id": "household contacts", "strength": 2}, {"source_id": "SARS-CoV-2 antibodies", "target_id": "cohort study", "strength": 2}, {"source_id": "closed cohort study", "target_id": "SARS-CoV-2 antibodies", "strength": 2}, {"source_id": "closed cohort study", "target_id": "retrospective closed cohort study", "strength": 2}, {"source_id": "COVID-19 vaccine hesitancy", "target_id": "vaccine characteristics", "strength": 2}, {"source_id": "vaccine characteristics", "target_id": "COVID-19 vaccine hesitancy", "strength": 2}, {"source_id": "second dose", "target_id": "mRNA vaccines", "strength": 2}, {"source_id": "mortality rate", "target_id": "herd immunity", "strength": 2}, {"source_id": "economic activity", "target_id": "policy analysis", "strength": 2}, {"source_id": "alternative policies", "target_id": "economic activity", "strength": 2}, {"source_id": "COVID-19 vaccine", "target_id": "Delta variant", "strength": 2}, {"source_id": "vaccine effectiveness", "target_id": "Delta variant", "strength": 2}, {"source_id": "Delta variant", "target_id": "COVID-19 vaccine effectiveness", "strength": 2}]}}